

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)


PCT

(10) International Publication Number
WO 03/034938 A2

- (51) International Patent Classification⁷: **A61F**
- (21) International Application Number: PCT/US02/34344
- (22) International Filing Date: 25 October 2002 (25.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/343,732 25 October 2001 (25.10.2001) US
- (71) Applicant (for all designated States except US): **WISCONSIN ALUMNI RESEARCH FOUNDATION** [US/US]; 614 Walnut Street, Madison, WI 53707-7365 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **WOLFF, Matthew, R.** [US/US]; 1332 North High Point Road, Middleton, WI 53562 (US).
- (74) Agents: **LEONE, Jos, T.** et al.; DeWitt Ross & Stevens S.C., 8000 Excelsior Drive, Madison, WI 53717-1914 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: VASCULAR STENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND METHOD OF USING SAME



(57) Abstract: Disclosed is a device, such as a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter, or vascular shunt, for stenting a blood vessel. The device has coated thereon, adsorbed thereto, impregnated therein, or covalently or ionically bonded thereto an amount of a protein tyrosine kinase inhibitor. The protein tyrosine kinase inhibitor proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the device, while simultaneously not inhibiting the proliferation of vascular intimal cells. A corresponding method of using the device to stent blood vessels is also disclosed.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

VASCULAR STENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND METHOD OF USING SAME

5

Matthew R. Wolff

RELATED APPLICATION

Priority is hereby claimed to provisional application Serial No. 60/343,732, filed October 25, 2001, which provisional application is incorporated herein by reference.

10

FIELD OF THE INVENTION

The invention is directed to methods of selectively inhibiting the proliferation of vascular smooth muscle cells (VSMCs) following vascular injury or surgical interventions such as percutaneous revascularization, without inhibiting the proliferation of endothelial cells. Specifically, the invention is directed to the use of protein tyrosine kinase inhibitors, preferably those that inhibit the Bcr-Abl tyrosine kinase, and most preferably 4-((4-methyl-1-piperazinyl)methyl)-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}benzamide methane sulfonate, coated onto vascular stents, native grafts, or prosthetic vascular grafts, to prevent the proliferation of VSMCs selectively, while not adversely affecting the proliferation of endothelial cells.

20

BACKGROUND

Arteriosclerosis is a class of diseases characterized by the thickening and hardening of the arterial walls of blood vessels. Although all blood vessels are susceptible to this serious degenerative condition, the aorta and the coronary arteries serving the heart are most often affected. Arteriosclerosis is of profound clinical importance since it can increase the risk of heart attacks, myocardial infarctions, strokes, and aneurysms.

25

The traditional treatment for arteriosclerotic vessels currently includes vascular recanalization procedures for less-serious blockages and coronary bypass surgery for major blockages. Where possible, vascular recanalization is much preferred to coronary bypass because it is a far less invasive procedure. Vascular recanalization procedures involve using

30

intravascular devices threaded through blood vessels to the obstructed site, including for example, percutaneous transluminal coronary balloon angioplasty (PTCA), also known as balloon angioplasty. Balloon angioplasty uses a catheter with a balloon tightly packed onto its tip. When the catheter reaches the obstruction, the balloon is inflated, and the atherosclerotic plaques are compressed against the vessel wall. A serious shortcoming of this and other intravascular procedures, however, is that in a significant number of treated individuals, some or all of the treated vessels restenose (that is, the vessels again narrow). This generally occurs in a relatively brief time period, roughly less than six months, after treatment. The restenosis is thought to be due in part to mechanical injury to the walls of the blood vessels caused by the balloon catheter or other intravascular device.

The walls of most blood vessels are composed of three distinct layers, or tunics, surrounding a central tubular opening, the vessel lumen. The innermost layer that lines the vessel lumen is called the tunica intima. The middle layer, the tunica media, consists mostly of circularly arranged smooth muscle cells and connective tissue fibers. In a non-injured vessel, the smooth muscle cells are generally not actively dividing. The outmost layer of the blood vessel wall, the tunica adventitia, is composed largely of collagen fibers that protect inner layers and gives the blood vessel structural integrity. Mechanical injury, resulting in damage to the tunica intima, initiates a cascade of events, including the release of chemicals such as platelet-derived growth factors (PDGF). This cascade prompts the migration and proliferation of vascular smooth muscle cells (VSMCs) at the site of injury. The accumulation of VSMCs at the site of injury narrows the diameter of the vessel lumen, thereby again putting the patient in danger of having a heart attack, stroke, etc.

Several methods for inhibiting smooth muscle cell proliferation following the use of an intravascular device have been reported in the patent literature. These include administering anti-proliferative agents such as cell cycle inhibitors and anti-coagulant agents (either by local or systemic delivery systems). Delivery of these agents systemically, however, has required dosages that cause unacceptable side-effects or are prohibitively expensive. Local delivery of agents, for example heparin, as described in U.S. Pat. No. 4,824,436, has proven ineffective in inhibiting restenosis due in part to inadequate residence time of the

active agent at the site of injury. Cell cycle inhibitors such as taxol, which do not react covalently and therefore require prolonged residence time for effectiveness, suffer from similar problems. Moreover, prolonging residence times to increase the effectiveness of such treatments is also likely to present increased risks of toxicity.

5 Other methods reported for inhibiting VSMC proliferation involve local delivery of active agents contained in a sustained-release formulation. For example, U.S. Pat. No. 5,171,217 describes agents contained within a physiologically compatible, biodegradable polymeric microparticle. This formulation is delivered locally to the site of injury such that the agents are released from the arterial wall for 72 hours or more. In contrast, U.S. Pat. No.
10 6,281,225 describes the local, but non-sustained-release administration of DNA alkylating agents to prevent VSMC proliferation.

Another method for inhibiting smooth muscle cell proliferation involves administering photochemically-activated agents by local delivery systems. For example, U.S. Pat. No. 5,354,774 describes locally delivering 8-methoxypsoralen to the site of injury and then
15 activating a photodynamic reaction using a visible light source.

Yet another approach to prevent proliferation of VSMCs is the use of radiation-emitting catheters or guide wires. These radioactive devices cause damage to nucleic acid, thus inhibiting replication and thereby inhibiting smooth muscle cell proliferation.

All of the above-described methods suffer from certain drawbacks. For example,
20 sustained release formulations require an added level of complexity, namely incorporation of the agent on or within a sustained release formulation. Photodynamic therapy requires both local delivery of the photo-active agent and the use of a complex intravascular light source. Delivery of a radiation dose requires the presence of a radiologist and presents exposure hazards to the attending personnel, as well as material storage, handling, and disposal
25 complications.

Treated coronary stents now on the market or in clinical trials also suffer from the distinct drawback that they inhibit the proliferation of endothelial cells. This contributes to thrombosis in the vicinity of deployed stent. Thrombosis has been observed in human clinical trials when using stents coated with either taxol or rapamycin. To prevent such thrombosis,
30 the clinical patients have had to undergo a two- to three-month duration anti-coagulation treatment.

A need therefore exists for safe, simple, and straightforward method for inhibiting VSMC proliferation at a site of injury following vascular recanalization procedures or other vascular injury, without inhibiting the proliferation of endothelial cells. The ideal solution should be non-radioactive and require little or no retraining of medical personnel to implement.

Cellular signaling has become a major research theme in biology and medicine over the past twenty years. The complex pathways and protein components in signal transduction are emerging only slowly, but with increasing clarity. Over the last 15 years, the protein tyrosine kinases have been identified as key players in cellular regulation. They are involved in immune, endocrine, and nervous system physiology and pathology and thought to be important in the development of many cancers, most notably chronic myeloid leukemia. As such they serve as drug targets for many different diseases. A host of protein tyrosine kinases are known in the art. The attached Sequence List includes a non-exclusive sampling of the amino acid sequences of a number of such kinases.

As used herein, the term protein tyrosine kinases (PTKs) refers to any and all enzymes falling within the enzyme classification EC 2.1.7.112, without limitation. See the Sequence List, attached hereto, for various examples of PTKs. These enzymes catalyze the transfer of the gamma-phosphoryl group from ATP to the tyrosine hydroxyl moiety of a protein substrate. This family of kinases shares amino acid sequence homology with the serine/threonine kinase family. Although the number of tyrosine kinases being discovered is growing exponentially, molecular details pertaining to their substrate recognition, catalytic mechanism, and intra- and intermolecular regulation are still being elucidated.

As described in full below, the present inventors have found that inhibiting the action of PTKs selectively inhibits the proliferation of VSMCs.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph depicting porcine coronary vascular smooth muscle cell proliferation following stimulation with platelet-derived growth factor (PDGF) in the presence of increasing concentrations of STI-571.

FIG. 2 is a graph depicting porcine aortic endothelial cell proliferation following stimulation with vascular endothelial growth factor (VEGF) in the presence of increasing concentrations of STI-571.

FIG. 3 is a graph depicting inhibition of proliferation of human coronary artery vascular smooth muscle cells (hCASMC) by increasing concentrations of STI-571 ("Glivec"). Cells were counted after stimulation with 10% fetal bovine serum (FBS) for 48 hours, and data for each experiment was normalized to positive control wells containing FBS and no STI-571 ("Glivec"). Each point represents 18 to 21 wells from eight separate experiments, and is presented as the mean +/- the standard deviation.

FIG. 4 is a graph depicting inhibition of DNA synthesis in human coronary artery vascular smooth muscle cells (HCAVSMC) by STI-571 ("Glivec"). DNA synthesis was assayed by incorporation of BrdU after stimulation of coronary artery vascular smooth muscle cells by 10% FBS for 48 hours in the presence or absence (positive control) of STI-571 ("Glivec"). Data points represent 14 to 28 wells from two separate experiments, and are presented as the mean +/- the standard deviation.

FIG. 5 is a graph depicting inhibition of migration of human coronary artery vascular smooth muscle cells in response to STI-571 ("Glivec"). Migration was assayed by counting cells that migrated through a porous membrane (20 μ m diameter pores) in 24 hours in response to stimulation with platelet-derived growth factor (PDGF- $\beta\beta$). Data bars represent six membranes, and are presented as means normalized to control membranes (no STI-571) +/- the standard deviation.

FIG. 6 is a graph depicting the lack of any effect of STI-571 ("Glivec") on the proliferation of human coronary artery endothelial cells (hCAEC).

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Definitions:

The following abbreviations and definitions are used throughout the specification and claims. Terms not specifically defined herein have their normal and accepted meaning within the field of cardiovascular medicine and/or physiology.

"BrdU" = 5-bromo-2'-deoxy-uridine triphosphate.

"DME" = Dulbecco's modified Eagle's media.

"FBS" = fetal bovine serum.

"JAK-2" = Janus-activated tyrosine kinases.

5 "MAPK" = mitogen-activated protein kinases.

"PDGF" = platelet-derived growth factor.

10 "Pharmaceutically-suitable salt" = any acid or base addition salt whose counter-ions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base or free acid PTK inhibitor are not vitiated by side effects ascribable to the counter-ions. A host of pharmaceutically-suitable salts are well known in the pharmaceutical field. For active ingredients that are bases, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a

15 pharmaceutically-suitable salt by ion exchange procedures. Pharmaceutically-suitable acid addition salts include, without limitation, those derived from mineral acids and organic acids, explicitly including hydrohalides, *e.g.*, hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates,

20 methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates, quinate, and the like. In analogous fashion, for active ingredients that are acids, pharmaceutically-suitable base addition salts may be used. Base addition salts include, without limitation, those derived from alkali or alkaline earth metal bases or

25 conventional organic bases, such as triethylamine, pyridine, piperidine, morpholine, N-methylmorpholine, and the like.

"PTCA" = percutaneous transluminal coronary balloon angioplasty.

"PTK" = protein tyrosine kinase; expressly defined herein as any and all enzymes falling within the enzyme classification EC 2.1.7.112, without limitation.

"PTK Inhibitor" = any compound or composition that selectively inhibits the catalytic activity of one or more protein tyrosine kinase inhibitors.

"STI-571" = 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyrimidinyl)amino)-phenyl]benzamide and pharmaceutically-suitable salts thereof. The methane-sulphonate salt is preferred. This compound has been given the trivial generic name "imatinib." As used herein, the term "STI-571" designates imatinib as either a free base or any pharmaceutically-suitable salt thereof, the mesylate salt being preferred. In the United States, it is marketed commercially by Novartis AG (Basel, Switzerland) under the registered trademark "Gleevec" (U.S. T.M. Registration No. 2,478,196); it is also sold elsewhere around the world under the trademark "Gleevec."

"VEGF" = vascular endothelial growth factor.

"VSMC" = vascular smooth muscle cells.

Overview:

Treating arteriosclerosis with intravascular devices, including for example, ablative procedures, balloon catheters, or vascular stents is becoming increasingly popular as technology related to intravascular devices continues to improve. Approximately 1 million balloon angioplasty procedures alone are performed on an annual basis globally. These procedures, however, have a major shortcoming. In a significant number of cases the treated vessels re-occlude, or restenose, by six months post-treatment which requires the individual to undergo additional treatment. "Restenosis" refers to the stage at which the vessel lumen has decreased in diameter by about 50% or more as compared to the diameter of the vessel lumen immediately following a vascular recanalization procedure.

The pathogenesis of restenosis is not well understood. It is believed to be due, in part, to recoil of the wall of the treated vessel. Additionally, it is hypothesized that vascular recanalization procedures used to treat diseases, such as arteriosclerosis, can cause mechanical injury at the site of recanalization. Without being limited to any particular mechanism of action, it is hypothesized that once intimal rupture occurs in the blood vessel a number of events begin to take place including the migration of monocytes to the

subendothelial layer of the intima and the release of mitogenic growth factors, including, for example, platelet-derived growth factor (PDGF), macrophage-derived growth factor (MDGF), and endothelial cell-derived growth factor (EDGF). These chemicals, and in particular PDGF, apparently play a role in inducing VSMC proliferation. This in turn produces substantial quantities of intercellular substances that accumulate within the vessel lumen, thereby narrowing its diameter.

A first embodiment of the present invention is therefore directed to a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt (collectively referred to herein as a "vascular device") that is coated with one or more compounds that selectively inhibit the proliferation of VSMCs at the point immediately adjacent to and proximal to the point of vascular injury. Specifically, the invention comprises a vascular device that has coated thereon, adsorbed thereto, impregnated therein, or covalently or ionically bonded thereto an amount of a protein tyrosine kinase (PTK) inhibitor. It is preferred that the compound specifically inhibit the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality found in chronic myeloid leukemia. Preferred PTK inhibitors for use in the invention are also those that specifically or non-specifically inhibit the activity of one or more PTKs selected from the group consisting of receptor tyrosine kinases for platelet-derived growth factor and stem cell factor (SCF), and c-Kit. The amount of the PTK used in conjunction with the vascular device is an amount sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the vascular device. In the preferred embodiment, the vascular device is coated with 4-{{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}benzamide and/or a pharmaceutically-suitable salt thereof (preferably the methane sulphonate salt).

A second embodiment of the invention is directed to a corresponding method for specifically preventing or inhibiting proliferation of VSMCs. Here, the method comprises coating, adsorbing, impregnating, or covalently or ionically bonding to the vascular device an amount of a PTK inhibitor; the amount being sufficient to prevent or inhibit proliferation of

VSMCs in an area within a blood vessel immediately adjacent to and/or proximal to the vascular device when the device is deployed within the lumen of a blood vessel. The preferred PTK inhibitor is 4-{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}benzamide and/or a pharmaceutically-suitable salt thereof.

5 A third embodiment of the invention is directed to a systemic method of preventing or inhibiting restenosis of blood vessels following vascular intervention. The method comprises systemically administering an amount of a PTK inhibitor (preferably orally), the amount administered being sufficient to prevent or inhibit proliferation of VSMCs in an area within a blood vessel immediately adjacent to and/or proximal to the area where the vascular
10 intervention took place. Again, the preferred PTK inhibitor for use in this embodiment of the invention is 4-{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}benzamide and/or a pharmaceutically-suitable salt thereof.

Compounds For Use In The Invention:

15 Any compound now known or discovered in the future that inhibits the action of PTKs can be used in the subject invention. Specific compounds whose anti-PTK activity has been documented, and thus can be used in the present invention, include (without limitation): pyridopyrimidines, phtalimides, chinolines, chinazolines, flavonoides, and benzothiazoles.

Among the most extensively studied PTK inhibitors are the tyrophostins and
20 quinazoline derivatives. These compounds are currently under investigation as potential anti-cancer drugs. For example, tyrophostins and quinazoline have been shown to synergize with antibodies to EGFR and to established anti-cancer drugs like cisplatin to inhibit the growth of squamous cell carcinoma *in vivo* and to block the growth of human cancer cells over expressing HER2-ErbB2 (respectively). Tyrophostins are based on the benzylidenemalonitrile
25 structure. Slight permutations in this structure have provided a range of potent inhibitors that selectively target EGFR, Erb-2 and v-Abl. Thus tyrophostins can be used alone or in combination with other PTK inhibitors to suppress VSMC proliferation into the lumen of blood vessels.


The quinazoline family of compounds includes the brominated quinazoline derivative,
30 an early EGFR inhibitor that was found to be more than 3-fold more potent than any other

tyrosine kinase inhibitor yet described (with an IC_{50} of 29 pM). In addition, it has little affinity for PDGFR, FGFR, insulin receptor, the CSF receptor and Src, even at micromolar concentrations. Because of this extraordinary inhibitory activity and specificity, the quinazoline derivatives are a major focus of research aimed at developing kinase inhibitors as anti-cancer agents. Thus, these compounds can also be used in the present invention, either alone or in combination with other PTK inhibitors.

Another group of PTK inhibitory compounds, dianilinophthalimides, were rationally designed from the natural product PTK inhibitor staurosporine aglycon (see Appendix C). These compounds have been shown to be competitive inhibitors of ATP and to date more than 250 dianilinophthalimide derivatives have been synthesized and evaluated for their biological activity. The derivative CGP5211 has displayed a good amount of specificity towards EGFR ($IC_{50}=3\text{mM}$), but also shows some inhibitory activity towards PKC. This observation led to the design of CGP53353 derivative, which showed lower specificity towards PKC isozymes. Thus, dianilinophthalimides can also be used as a PTK inhibitor in the present invention.

A large number of other compounds are known to be PTK inhibitors. These compounds, all of which can be used in the present invention, include bryostatins, defensins, genistein, H8, herbimycin A, tyrophostins, K-252a, lavendustin A, phorbol esters, staurosporines, and suramin.

The preferred PTK inhibitor for use in the present invention is 4-((4-methyl-1-piperazinyl)methyl)-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}benzamide and pharmaceutically-suitable salts thereof (preferably the mesyl salt):



This compound, originally designated STI-571, is marketed commercially in the United States by Novartis under the trademark "Glivec." It is approved by the U.S. Food and Drug Administration for the treatment of chronic myeloid leukemia. See EP 0 564 409 A and WO 99/03854.

15

Modes of Administration:

One embodiment of the invention is a method of preventing restenosis of blood vessels following a vascular injury or intervention by systemically administering one or more PTK inhibitors. The preferred route is orally. The PTK inhibitor may also be administered

20 intravenously, intra-arterially, intramuscularly, percutaneously, parenterally, or rectally.

Specifically, systemic or topical administration is accomplished via a pharmaceutical composition comprising an active compound, *i.e.*, a PTK inhibitor or a pharmaceutically-acceptable salt thereof, in combination with an acceptable carrier therefor and optionally in combination with other therapeutically-active ingredients or inactive accessory ingredients.

25 The carrier must be pharmaceutically-acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient. Suitable pharmaceutical compositions include those suitable for oral, topical (*i.e.* intra-lumen), rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. The term "unit dosage" or "unit dose" is denoted to mean a predetermined amount of the active ingredient sufficient to be effective for treating an indicated activity or condition. Making each type of pharmaceutical composition includes the step of bringing the active compound into association with a carrier and one or more optional accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid or solid carrier and then, if necessary, shaping the product into the desired unit dosage form.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, boluses or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or in liquid form, *e.g.*, as an aqueous solution, suspension, syrup, elixir, emulsion, dispersion, or the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form, *e.g.*, a powder or granules, optionally mixed with accessory ingredients, *e.g.*, binders, lubricants, inert diluents, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active compound with any suitable carrier.

Formulations suitable for parenteral administration conveniently comprise a sterile preparation of the active compound in, for example, water for injection, saline, a polyethylene glycol solution and the like, which is preferably isotonic with the blood of the recipient.

Useful formulations also comprise concentrated solutions or solids containing the PTK-inhibitory compound, which upon dilution with an appropriate solvent give a solution suitable for parenteral administration.

Preparations for topical or local applications comprise aerosol sprays, lotions, gels, ointments, suppositories etc., and pharmaceutically-acceptable vehicles therefore such as water, saline, lower aliphatic alcohols, polyglycerols such as glycerol, polyethylene glycerol,

esters of fatty acids, oils and fats, silicones, and other conventional topical carriers. In topical formulations, the PTK inhibitors are preferably utilized at a concentration of from about 0.1% to 5.0% by weight.

5 Compositions suitable for rectal administration, comprise a suppository, preferably bullet-shaped, containing the active ingredient and pharmaceutically-acceptable vehicles therefore such as hard fat, hydrogenated cocoglyceride, polyethylene glycol and the like. In suppository formulations, the PTK inhibitors are preferably utilized at concentrations of from about 0.1% to 10% by weight.

10 Compositions suitable for rectal administration may also comprise a rectal enema unit containing the active ingredient and pharmaceutically-acceptable vehicles therefore such as 50% aqueous ethanol or an aqueous salt solution which is physiologically compatible with the rectum or colon. The rectal enema unit consists of an applicator tip protected by an inert cover, preferably comprised of polyethylene, lubricated with a lubricant such as white petrolatum and preferably protected by a one-way valve to prevent back-flow of the
15 dispensed formula, and of sufficient length, preferably two inches, to be inserted into the colon via the anus. In rectal formulations, the PTK inhibitors are preferably utilized at concentrations of from about 5.0-10% by weight.

Useful formulations also comprise concentrated solutions or solids containing the active ingredient which upon dilution with an appropriate solvent, preferably saline, give a
20 solution suitable for rectal administration. The rectal compositions include aqueous and non-aqueous formulations which may contain conventional adjuvants such as buffers, bacteriostats, sugars, thickening agents and the like. The compositions may be presented in rectal single dose or multi-dose containers, for example, rectal enema units.

25 Preparations for topical or local surgical applications for treating a blood vessel within its lumen comprise swabs or catheters suitable for such purposes. In both topical or local surgical applications, the sterile preparations of PTK inhibitor are preferably utilized at concentrations of from about 0.1% to 5.0% by weight applied to a dressing.

30 Compositions suitable for administration by inhalation include formulations wherein the active ingredient is a solid or liquid admixed in a micronized powder having a particle size in the range of about 5 microns or less to about 500 microns or liquid formulations in a

suitable diluent. These formulations are designed for rapid inhalation through the oral passage from a conventional delivery systems such as inhalers, metered-dose inhalers, nebulizers, and the like. Suitable liquid nasal compositions include conventional nasal sprays, nasal drops and the like, of aqueous solutions of the active ingredient(s).

5 In addition to the aforementioned ingredients, the formulations of this invention may further include one or more optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, i.e., diluents, buffers, flavoring agents, colorants, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including antioxidants) and the like.

10 The amount of the PTK inhibitor required to be effective for inhibiting VSMC proliferation will, of course, vary with the individual mammal being treated and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, the nature of the formulation, the mammal's body weight, surface area, age and general condition, and the particular PTK
15 inhibitor to be administered. In general, a suitable effective dose is in the range of about 0.01 to about 500 mg/kg body weight per day of the selected PTK inhibitor. The total daily dose may be given as a single dose, multiple doses, *e.g.*, two to six times per day, or by intravenous infusion for a selected duration. Dosages above or below the range cited above are within the scope of the present invention and may be administered to the individual patient if desired
20 and necessary.

The PTK inhibitors may be administered prophylactically (in the preferred embodiment immediately post-surgery), chronically, or acutely.

Specifically addressing the preferred embodiment, Novartis sells STI-571 in capsules that provide the equivalent of 100 mg of the free base form of STI-571. When administered
25 orally (the preferred route), the preferred amount of STI-571 for use in the present invention is from 100 to 800 mg daily, taken in from one to four equal doses. Considerably larger doses, up to 1,200 mg/m²/day, may also be given. Doses above 1,200 mg/m²/day are not recommended.

The methods of the present invention include the administration, by local delivery to a site of injury, of compounds that have the ability to inhibit PTK activity. Non-limiting examples of local delivery systems for use in the present invention include intravascular drug delivery catheters, wires, pharmacological stents and endoluminal paving.

5 In the preferred embodiment using local delivery, the compounds for use in the present invention are administered to the site of recanalization by direct intravascular deposition using intravascular catheters. Catheter systems for use in the present invention, include, for example, pressure-driven catheters, diffusion catheters and mechanical catheters. Pressure-driven catheter systems that can be used in the present invention include porous
10 catheters; microporous catheters, for example, those made by Cordis Corporation; macroporous catheters; transport catheters, for example, those made by Cardiovascular Dynamics/Boston Scientific; channeled balloon catheters, for example, those made by Boston Scientific; and infusion sleeve catheters, for example, those made by LocalMed. See, for example, U.S. Pat. No. 5,279,565.

15 The PTK inhibitors may also be administered locally via diffusion-based catheter systems, including for example, double balloon, dispatch, hydrogel and coated stent catheters. The methods of the invention also include local administration of the compounds used in the methods of the present invention by mechanical device-based catheter systems, such as iontophoretic balloon catheters.

20 The compounds for use in the present invention may be administered by local delivery at a time proximal to the recanalization procedure or at a time after the recanalization procedure. The compounds for use in the invention may be delivered in a single dose or delivered in repeat doses.

25 The ability to deliver the PTK inhibitory compounds used in the present invention may be evaluated *in vivo* using known animal models, including the porcine coronary model described in the Examples. Thus, for example, a PTK inhibitor to be used in the methods of the present invention is administered by local delivery to a porcine at a site of vascular injury. The porcine is sacrificed and then examined by known cytological, histological, and other methods, including, for example, fluorescence microscopy.

Optimum conditions for delivery of the PTK inhibitory compounds for use in the methods of the invention may vary with the different local delivery systems used, as well as the properties and concentrations of the compounds used. Conditions may be optimized for inhibition of VSMC proliferation at the site of injury such that significant arterial blockage due to restenosis does not occur, as measured, for example, by the proliferative ability of the VSMCs, or by changes in the vascular resistance or lumen diameter. Conditions which may be optimized include, for example, the concentrations of the compounds, the delivery volume, the delivery rate, the depth of penetration of the vessel wall, the proximal inflation pressure, the amount and size of perforations and the fit of the drug delivery catheter balloon.

In a particularly preferred route of administration, the PTK inhibitory compound is coated or adsorbed onto a vascular stent, a prosthetic venous/arterial graft, or an autologous vascular graft. Alternatively, the PTK inhibitor may be impregnated therein, or covalently or ionically bonded thereto.

The preferred application of the PTK inhibitor to the stent, graft, or prosthesis is by conventional methods which are known in the art. These methods include, without limitation, dipping, steeping and spraying the article with the PTK inhibitor. Additional coating and impregnation techniques using pressure to force the coating into the substrate interstices are also contemplated. Multiple layers of the bio-active coating may be applied to the article. The stent, graft or prosthesis may first be coated with a polymeric coating to provide sustained release of the PTK inhibitor over a period of days, week, or months. Preferably, from about 1 to about 10 layers of the PTK inhibitory agent are applied to the surface of the stent, graft, or prosthesis.

Devices and Autologous Grafts According to the Invention:

As noted in the previous paragraph, one preferred route to administer the PTK inhibitory compounds is to adhere them onto a stent, autologous graft, or vascular prosthesis. In the present invention, any such vascular medical device may be used, including catheters, stents, sheets, tubes, balloons, and the like. The term "medical device" as used herein shall generically designate all such vascular medical devices, whether synthetic, semi-synthetic, or autologous tissue or material.

Preferably the medical device of the present invention is an implantable device such as a vascular graft, endoprosthesis or stent, that has been treated, coated, or otherwise manipulated to have coated on at least one surface a compound that inhibits PTK activity. For purposes of this invention, the term "vascular graft" is meant to include all endoprostheses which are generally introduced via catheter. In the preferred embodiment, the medical device is coated with STI-571. Other medical devices may also be coated, such as catheters which are minimally invasive. The vascular graft may include a hollow tubular body having an inner and an outer hydrophobic surface, the outer surface or both surfaces of which are coated with the PTK inhibitory compound.

Most preferably, the device of the present invention is a small caliber vascular stent or graft, made of metal or polymeric material (such as poly(tetrafluoroethylene)). This includes stents made of polymeric materials and coated with distinct materials, such as the polytetrafluoroethylene stent described in U.S. Pat. No. 6,306,165.

Vascular stents, the preferred medical device of the subject invention, are miniature mesh tubes that are implanted in the arteries to keep blocked portions open after angioplasty procedures. Working as scaffolding for the treated artery, stents are flexible yet quite strong, are generally easy (for a skilled physician) to deliver via catheter, and are readily seen on a fluoroscope. Stents are pre-mounted on balloon catheters which are used to deliver the stent to the treatment site and then expand the stent into place after the blockage is cleared.

Any stent now known or developed in the future can be coated with a PTK inhibitor according to the present invention. Perhaps the largest commercial supplier of vascular stents is Medtronic, 710 Medtronic Parkway, Minneapolis, Minnesota. Medtronic also has facilities located in Tolochenaz, Switzerland; Ontario, Canada; Causeway Bay, Hong Kong; and Gladesville, NSW, Australia. All of Medtronic's stents, catheters, balloons, guide catheters, guidewires, and the like can be used in the present invention. Currently, Medtronic markets a very wide range of stents and other vascular medical devices under the "Discrete Technology," "S7," "S670," "S660," and "BeStent" trademarks.

Vascular stents are available from non-US-based manufacturers as well. For example, Biocompatibles Cardiovascular, of Farnham, United Kingdom, manufactures and sells a range of cardiovascular stents under the trademark "BiodivYsio."

The PTK inhibitor can be adhered or coated onto the medical device, or it can be chemically bonded, either covalently or ionically to the medical device. The PTK inhibitor may be bonded directly to the medical device, or bonded via a spacer group or linker. For covalent attachment, it is preferred that a polymeric medical device, or a polymer-coated medical device be used and that the PTK inhibitor be covalently bonded to the medical device via a spacer group or linker having a chain length of from 1 to 250 atoms. For example, the spacer group may include an alkyls, alkylamines, oxygenated polyolefins, aliphatic polyesters, polyamino acids, polyamines, hydrophilic polysiloxanes, hydrophilic polysilazanes, hydrophilic acrylates, hydrophilic methacrylates, linear and lightly branched polysaccharides, and the like.

In yet another embodiment of the invention, there is provided a surface-modified implantable sheet material whose treated surface when exposed to the intimal layer of a blood vessel exhibits anti-VSMC proliferation activity over extended periods of time. This implantable sheet material includes a hydrophobic substrate material having adhered or bonded thereto a compound that inhibits PTK activity, the preferred compound being STI-571. The sheet can be formed into surgical mesh patches or tubes to repair vascular defects and injuries.

EXAMPLES

The following Examples are included solely to provide a more thorough disclosure of the invention claimed herein. The Examples do not limit the invention in any fashion.

Example 1 - Vascular Smooth Muscle Cell Proliferation:

Porcine coronary VSMCs were grown to subconfluence in 96-well plates with DME media containing 10% FBS at 37°C for 3 to 5 days. After synchronization in serum-free DME media for 48 hours, the cells were stimulated with PDGF (20 ng/mL) for 24 hours, in the presence of STI-571 (0.01 to 10 M). BrdU was added to the wells for the last 5 hours of the stimulation period. The cells were subsequently dried for 24 hours at 60°C, fixed and denatured, and BrdU incorporation was determined using a colorimetric assay (ELISA) sold commercially by Roche Molecular Biochemicals (catalog no. 1,647,229), following the

manufacturer's protocol. See "Cell Proliferation ELISA, BrdU (Colorimetric) Instruction Manual," Version 3, September 2000, available from Roche Molecular Biochemicals. Briefly, the BrdU ELISA is a colorimetric immunoassay for quantification of cell proliferation. It is based on the measurement of BrdU incorporation during DNA synthesis. The colorimetric approach is a non-radioactive alternative to the equivalent ^3H -thymidine incorporation assay. See also Example 4.

The results of this Example are presented graphically in Fig. 1. DNA synthesis was assayed by incorporation of BrdU (in the same fashion as described in Example 4) after stimulation of the cells with platelet-derived growth factor (PDGF- $\beta\beta$, 20 ng/ml) for 48 in the presence or absence (positive control) of STI-571. Each data point represents 5 to 7 wells, and is expressed as the mean \pm the standard deviation.

As can be seen from the figure, administration of STI-571 inhibited the proliferation of VSMCs in a dose-dependent fashion. This Example demonstrates the utility of the present invention to inhibit the proliferation of VSMCs.

Example 2 - Vascular Endothelial Cell Proliferation:

Porcine aortic vascular endothelial cells were grown to subconfluence in 96-well plates with DME media containing 10% FBS at 37°C for 3 to 5 days. After synchronization in serum-free DME media for 48 hours, the cells were stimulated with VEGF (20 ng/mL) for 24 hours, in the presence of STI-571 (0.01 to 10 M). BrdU was added to the wells for the last 5 hours of the stimulation period. The cells were subsequently dried for 24 hours at 60°C, fixed and denatured, and BrdU incorporation determined using the Roche ELISA described in Example 1.

The results of this Example are presented graphically in Fig. 2. As can be seen from this figure, STI-571 had a very minimal inhibitory effect on the proliferation of aortic vascular endothelial cells.

Taken in conjunction with the results of Example 1, this Example demonstrates the utility of the present invention to inhibit the proliferation of VSMCs selectively, while not having an appreciable inhibitory effect on the proliferation of aortic vascular endothelial cells.

Example 3 - Inhibition of Proliferation of Human Coronary Artery Vascular Smooth Muscle Cells by Increasing Concentrations of STI-571:

This Example demonstrates that human coronary artery vascular smooth muscle cells are inhibited in a dose-dependent fashion by STI-571.

5 Cryopreserved human coronary artery vascular smooth muscle cells (CC-2583) were purchased commercially from Clonetics (now a wholly-owned subsidiary of Cambrex Bio Science Walkersville, Inc., Walkersville, Maryland).

10 The cells were grown in canted-neck, filtered-cap, 25cm² culture flasks, at an initial seed density of 2500 cells per cm². The cells were grown in "SmGM-2"-brand smooth muscle growth medium (Cambrex, used as delivered from the manufacturer) plus 10% FBS in a humidified 37 °C, 5% CO₂ incubator. Media were changed initially after 24 hours, and then every 48 hrs subsequently. The cells were passed at approximately 80% confluency (~ 4-6 days). The proliferation assays were performed in 24-well culture plates.

15 On day 5, growth media were replaced with test media (growth media + STI-571), growth media (positive control, media + FBS), and serum-free media (negative control, the "SmGM-2"-brand media without any added FBS).

20 Cells were counted manually trypsinizing the cells on day 7, with each condition (3 wells) pooled into one micro-centrifuge tube. The cells were spun at 1.5 X g for 10 min. and then resuspended in 60 µl trypsin-neutralizing solution. The cells were then counted on a hemacytometer in quadruplicate.

25 The results are shown in Fig. 3. In the figure, cells were counted after being stimulated with 10% FBS for 48 hours. The data for each experiment was normalized to positive control wells containing FBS and no STI-571. Each point represents 18 to 21 wells from eight separate experiments. The center of each data point is the mean at each concentration of STI-571, and the error bars are the standard deviation at each concentration level.

30 The significance of this graph is that it clearly indicates that STI-571 inhibits, in a dose-dependent fashion, the proliferation of human coronary artery vascular smooth muscle cells. Because these cells are responsible for restenosis, this graph demonstrates the effectiveness of the present invention for inhibiting such restenosis.

Example 4 - Inhibition of DNA Synthesis in Human Coronary Artery Vascular Smooth Muscle Cells by STI-571:

This example demonstrates that STI-571 inhibits DNA synthesis in human coronary artery vascular smooth muscle cells.

The same cells as described in Example 3 were used. Culture conditions and exposure to the various test concentrations of STI-571 were also the same as in Example 3.

DNA incorporation was measured using a commercially-available BrdU assay (Roche Molecular Biochemicals, catalog no. 1,647,229). The BrDu labeling solution was added on day 6, and the cells then allowed to incubate for another 24 hrs (through day 7). The label solution was then removed and the cells were dried at 60 °C for one hour. The cells were then fixed using "FixDenat" fixing solution for one hour at room temperature. The fixing solution was then removed and anti-BrdU antibody solution added to the cells. The cells were then incubated for 2 hr at 37 °C.

The antibody solution was then removed substrate added to the wells. The plates were incubated at room temperature until sufficient color development occurred. The reactions were stopped by adding 1 M H₂SO₄ to the wells. The absorbance was then measured at 450nm (reference, 690 nm).

The results are shown in Fig. 4. Each data point represents 14 to 28 wells from two separate experiments, and are expressed as the means +/- the standard deviations. The significance of this Example is that it shows that STI-571 inhibits DNA synthesis in human coronary artery vascular smooth muscle cells. As in the previous Example, this is notable because these types of cells cause restenosis of stented vessels. By inhibiting the growth of such cells, restenosis is inhibited.

Example 5 - Inhibition of Migration of Human Coronary Artery Vascular Smooth Muscle Cells by STI-571:

This Example was performed to determine if STI-571 has any effect on the migration of human coronary vascular smooth muscle cells.

The cells described in Example 3 were used. The initial seed density was 4000 cells per filter (0.3 cm²) in test media with 1% BSA and 20 ng/ml PDGF-ββ. The cells were then incubated in a humidified environment at 37 °C, 5% CO₂ for 24 hrs. The cells on the top side of the filter were then scraped away. The cells on bottom side of the filters were then fixed with ice-cold methanol for 10 min. The filters were rinsed with PBS and then stained with HarrisÆ Hematoxylin stain for 5 min. and again rinsed with PBS.

The cells were then counted manually under high-power magnification (400X) in quadruplicate.

The results are shown in Fig. 5. Data bars represent 6 membranes, and the data are presented as means normalized to control membranes (no STI-571) +/- standard deviations.

The significance of this Example is that it demonstrates that STI-571 inhibits the migration of human coronary vascular smooth muscle cells in a dose-dependent fashion. Because migration of these cells is a major contributor to restenosis after deployment of a stent, this Example demonstrates that the present invention can be used to inhibit this migration and hence inhibit restenosis.

Example 6 - Lack of Inhibitory Effect of STI-571 on Proliferation of Human Coronary Artery Endothelial Cells:

This Example demonstrates that the growth of human coronary artery endothelial cells are not inhibited in any fashion by STI-571.

Cyropreserved human coronary artery endothelial cells were purchased commercially from Clonetics (now a wholly-owned subsidiary of Cambrex Bio Science Walkersville, Inc., Walkersville, Maryland).

The cells were grown in canted-neck, filtered-cap, 25cm² culture flasks, at an initial seed density of 2500 cells per cm². The cells were grown in "EGM-MV"-brand smooth muscle growth medium (Cambrex, used as delivered from the manufacturer) plus 10% FBS in a humidified 37 °C, 5% CO₂ incubator. Media were changed initially after 24 hours, and then every 48 hrs subsequently. The cells were passed at approximately 80% confluency (~4-6 days). The proliferation assays were performed in 24-well culture plates.

On day 5, growth media were replaced with test media (growth media + STI-571), growth media (positive control, media + FBS), and serum-free media (negative control, the "EGM-MV"-brand media without any added FBS).

Cells were counted manually trypsinizing the cells on day 7, with each condition (3 wells) pooled into one micro-centrifuge tube. The cells were spun at 1.5 X g for 10 min. and then resuspended in 60 μ l trypsin-neutralizing solution. The cells were then counted on a hemacytometer in quadruplicate.

The results are shown in Fig. 6. As can be seen from the figure, STI-571 did not have a significant effect on the proliferation of human coronary artery endothelial cells at any of the STI-571 concentrations tested. This Example, in conjunction with Examples 3-5, are significant because they show that STI-571 has a profound inhibitory effect on human vascular smooth muscle cells (inhibits proliferation, DNA replication, and cell migration), but does not inhibit the proliferation of endothelial cells. This is notable because the proliferation of endothelial cells around an inserted vascular stent is desirable so that the stent becomes firmly implanted within the vessel wall.

CLAIMS

What is claimed is:


1. A device for stenting a blood vessel, the device comprising:
a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter, or vascular shunt having coated thereon, adsorbed thereto, impregnated therein, or covalently or ionically bonded thereto an amount of a protein tyrosine kinase inhibitor; the amount being sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt, while simultaneously not inhibiting the proliferation of vascular intimal cells.
2. The device of Claim 1, comprising a cardiovascular stent,
3. The device of Claim 1, comprising an autologous venous/arterial graft.
4. The device of Claim 1, comprising a prosthetic venous/arterial graft.
5. The device of Claim 1, comprising a vascular catheter.
6. The device of Claim 1, comprising a vascular shunt.
7. The device of Claim 1, wherein the protein tyrosine kinase inhibitor is a platelet-derived growth factor inhibitor.
8. The device of Claim 7, wherein the protein tyrosine kinase inhibitor is also a Bcr-Abl tyrosine kinase inhibitor.

9. The device of Claim 1, wherein the protein tyrosine kinase inhibitor is STI-571.
10. The device of Claim 1, wherein the protein tyrosine kinase inhibitor is 4-{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{4-(3-pyrimidinyl)amino}-phenyl}benzamide and/or a pharmaceutically-suitable salt thereof; the amount being sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt.
11. A device for stenting a blood vessel, the device comprising:
a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter, or vascular shunt having coated thereon, adsorbed thereto, impregnated therein, or covalently or ionically bonded thereto an amount of 4-{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{4-(3-pyrimidinyl)amino}-phenyl}benzamide and/or a pharmaceutically-suitable salt thereof; the amount being sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt, while simultaneously not inhibiting the proliferation of vascular intimal cells.
12. The device of Claim 11, comprising a cardiovascular stent,
13. The device of Claim 11, comprising an autologous venous/arterial graft.
14. The device of Claim 11, comprising a prosthetic venous/arterial graft.
15. The device of Claim 11, comprising a vascular catheter.

16. The device of Claim 11, comprising a vascular shunt.
17. A method of preventing restenosis following vascular intervention, the method comprising coating, adsorbing, impregnating, or covalently or ionically bonding to a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt used in the vascular intervention an amount of a protein tyrosine kinase inhibitor; the amount being sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt, while simultaneously not inhibiting the proliferation of vascular intimal cells.
18. The method of Claim 17, wherein the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt is coated with a platelet-derived growth factor inhibitor.
19. The method of Claim 17, wherein the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt is coated with a Bcr-Abl tyrosine kinase inhibitor.
20. The device of Claim 17, wherein the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt is coated with STI-571.
21. The device of Claim 17, wherein the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt is coated with 4-{{(4-methyl-1-piperazinyl)methyl}-N-{4-methyl-3-{{4-(3-pyrimidinyl)amino}-phenyl}}benzamide and/or a pharmaceutically-suitable salt thereof.


22. A method of preventing restenosis following vascular intervention, the method comprising coating, adsorbing, impregnating, or covalently or ionically bonding to a cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt used in the vascular intervention an amount of 4-{{(4-methyl-1-piperazinyl)methyl}}-N-{{4-methyl-3-{{4-(3-pyrimidinyl)amino}}-phenyl}}benzamide and/or a pharmaceutically-suitable salt thereof; the amount being sufficient to prevent or inhibit proliferation of vascular smooth muscle cells in an area within a blood vessel immediately adjacent to and/or proximal to the cardiovascular stent, autologous venous/arterial graft, prosthetic venous/arterial graft, vascular catheter or vascular shunt, while simultaneously not inhibiting the proliferation of vascular intimal cells.

1/6


**FIG. 1**

2/6

Porcine Aortic Endothelial Cells

**FIG. 2**

3/6

**FIG. 3**

Inhibition of DNA Synthesis in HCAVSMC by Glivec






FIG. 4

5/6

**FIG. 5**

6/6

**FIG. 6**

STENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
SEQUENCE LISTING

<110> Wolff, Matthew R.

<120> VASCULAR STENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN

<130> 09820.189

<150> 60/343,732

<151> 2001-10-25

<160> 25

<170> PatentIn version 3.1

<210> 1

<211> 3000

<212> DNA

<213> Homo sapiens

<400> 1

atggggccgg ccccgtgcc gctgctgctg ggctcttcc tccccgcgct ctggcgtaga
60gctatcactg aggcaaggga agaagccaag ccttaccgc tattcccggg accttttcca 1
20gggagcctgc aaactgacca cacaccgctg ttatcccttc ctacgccag tgggtaccag 1
80cctgccttga tgttttcacc aaccagcct ggaagaccac atacaggaaa cgtagccatt 2
40ccccaggaga cctctgtcga atcaaagccc ctaccgcctc ttgccttcaa acacacagtt 3
00ggacacataa tacttttctga acataaagggt gtcaaattta attgctcaat caatgtacct 3
60aatatatacc aggacaccac aatttcttgg tggaaagatg ggaaggaatt gcttggggga 4
20catcatcgaa ttacacagtt ttatccagat gatgaagtta cagcaataat cgcttccttc 4
80agcataacca gtgtgcagcg ttcagacaat gggtcgata tctgtaagat gaaaataaac 5
40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
aatgaagaga tcgtgtctga tcccatctac atcgaagtac aaggacttcc tcactttact 6
00

aagcagcctg agagcatgaa tgtcaccaga aacacagcct tcaacctcac ctgtcaggct 6
60

gtgggcccgc ctgagcccggt caacattttc tgggttcaaa acagtagccg tgtaaacgaa 7
20

cagcctgaaa aatcccccggt cgtgctaact gttccaggcc tgacggagat ggcggtcttc 7
80

agttgtgagg ccacacaatga caaagggtg accgtgtccc agggagtga gatcaacatc 8
40

aaagcaattc cctccccacc aactgaagtc agcatccgta acagcactgc acacagcatt 9
00

ctgatctcct gggttcctgg ttttgatgga tactccccgt tcaggaattg cagcattcag 9
60

gtcaaggaag ctgatccgct gggtaatggc tcagtcatga tttttaacac ctctgcctta 10
20

ccacatctgt accaaatcaa gcagctgcaa gccctggcta attacagcat tgggtgtttcc 10
80

tgcatgaatg aaataggctg gtctgcagtg agcccttgga ttctagcaag cacgactgaa 11
40

ggagccccat cagtagcacc tttaaatgtc actgtgtttc tgaatgaatc tagtgataat 12
00

gtggacatca gatggatgaa gcctccgact aagcagcagg atggagaact ggtgggctac 12
60

cgatatccc acgtgtggca gagtgcaggg atttccaaag agctcttgga ggaagttggc 13
20

cagaatggca gccgagctcg gatctctgtt caagtccaca atgctacgtg cacagtgagg 13
80

attgcagccg tcaccagagg gggagttggg cccttcagtg atccagtga aatatttatc 14
40

cctgcacacg gttgggtaga ttatgcccc tcttcaactc cggcgccctg caacgcagat 15
00

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
cctgtgctca tcatctttgg ctgcttttgt ggatttatatt tgattgggtt gattttatac 15
60

atctccttgg ccatcagaaa aagagtccag gagacaaagt ttgggaatgc attcacagag 16
20

gaggattctg aattagtggg gaattatata gcaaagaaat ccttctgtcg gcgagccatt 16
80

gaacttacct tacatagctt gggagtcagt gaggaactac aaaataaact agaagatgtt 17
40

gtgattgaca ggaatcttct aattcttggg aaaattcttg gtgaaggaga gtttgggtct 18
00

gtaatggaag gaaatcttaa gcaggaagat gggacctctc tgaaagtggc agtgaagacc 18
60

atgaagttgg acaactcttc acatcgggag atcgaggagt ttctcagtga ggcagcgtgc 19
20

atgaaagact tcagccaccc aaatgtcatt cgacttctag gtgtgtgtat agaaatgagc 19
80

tctcaaggca tcccaaagcc catggttaatt ttacccttca tgaaatacgg ggacctgcat 20
40

acttacttac tttattcccg attggagaca ggaccaaagc atattcctct gcagacacta 21
00

ttgaagttca tgggtgatat tgccctggga atggagtatc tgagcaacag gaattttctt 21
60

catcgagatt tagctgctcg aaactgcatg ttgcgagatg acatgactgt ctgtgttgcg 22
20

gacttcggcc tctctaagaa gatttacagt ggcgattatt accgccaagg ccgcattgct 22
80

aagatgcctg ttaaattggat cgccatagaa agtcttgcag accgagtcta cacaagtaaa 23
40

agtgatgtgt gggcatttgg cgtgaccatg tgggaaatac gtacgcgggg aatgactccc 24
00

tatcctgggg tccagaacca tgagatgtat gactatcttc tccatggcca caggttgaag 24
60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 cagccccgaag actgcctgga tgaactgtat gaaataatgt actcttgctg gagaaccgat 25
 20

cccttagacc gccccacctt ttcagtattg aggctgcagc tagaaaaact cttagaaagt 25
 80

ttgcctgacg ttcggaacca agcagacggt atttacgtca atacacagtt gctggagagc 26
 40

tctgagggcc tggcccaggg cccccacctt gotccactgg acttgaacat cgaccctgac 27
 00

tctataattg cctcctgcac tccccgcgct gccatcagtg tggtcacagc agaagttcat 27
 60

gacagcaaac ctcatgaagg acggtacatc ctgaatgggg gcagtgagga atgggaagat 28
 20

ctgacttctg cccctctgc tgcagtcaca gctgaaaaga acagtgtttt accgggggag 28
 80

agacttggtta ggaatggggt ctcttggtcc cattcgagca tgctgccctt gggaagctca 29
 40

ttgcccgatg aacttttggt tgctgacgac tcctcagaag gctcagaagt cctgatgtga 30
 00

<210> 2

<211> 1353

<212> DNA

<213> Homo sapiens

<400> 2

atgtcagcaa tacaggccgc ctggccatcc ggtacagaat gtattgcaa gtacaacttc
 60

cacggcactg ccgagcagga cctgcccttc tgcaaaggag acgtgctcac cattgtggcc 1
 20

gtaccaagg accccaactg gtacaaagcc aaaaacaagg tgggccgtga gggcatcatc 1
 80

ccagccaact acgtccagaa gcgggagggc gtgaaggcgg gtaccaaact cagcctcatg 2
 40

ccttggttcc acggcaagat cacacgggag caggctgagc ggcttctgta cccgccggag 3
 00

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

acaggcctgt tcctggtgcg ggagagcacc aactaccccg gagactacac gctgtgctg 3
60

agctgcgacg gcaagggtga gcactaccgc atcatgtacc atgccagcaa gctcagcatc 4
20

gacgaggagg tgtactttga gaacctcatg cagctggtgg agcactacac ctcagacgca 4
80

gatggactct gtacgcgcct cattaaacca aaggatcatgg agggcacagt ggcgggccag 5
40

gatgagttct accgcagcgg ctggggccctg aacatgaagg agctgaagct gctgcagacc 6
00

atcggaagg gggagttcgg agacgtgatg ctgggcgatt accgagggaa caaagtcgcc 6
60

gtcaagtgca ttaagaacga cgccactgcc caggccttcc tggctgaagc ctcagtcatg 7
20

acgcaactgc ggcatagcaa cctggtgcag ctctggggcg tgatcgtgga ggagaagggc 7
80

gggctctaca tcgtcactga gtacatggcc aaggggagcc ttgtggacta cctgcgggtct 8
40

aggggtcggg cagtgcctgg cgagactgt ctctcaagt tctcgctaga tgtctgcgag 9
00

gccatggaat acctggaggg caacaatttc gtgcacgag acctggctgc ccgcaatgtg 9
60

ctggtgtctg aggacaacgt ggccaaggtc agcgactttg gtctcaccaa ggaggcgtcc 10
20

agcaccagc acacgggcaa gctgccagtc aagtggacag cccctgaggc cctgagagag 10
80

aagaaattct ccaactaagtc tgacgtgtgg agtttcggaa tccttctctg ggaaatctac 11
40

tcctttgggc gagtgcctta tccaagaatt cccctgaagg acgtcgtccc tcgggtggag 12
00

aagggtctaca agatggatgc ccccgacggc tgcccggccg cagtctatga agtcatgaag 12
60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

aactgctggc acctggacgc cgccatgcgg ccttccttcc tacagctccg agagcagctt 13
20

gagcacatca aaacccacga gctgcacctg tga 13
53

<210> 3

<211> 3768

<212> DNA

<213> Homo sapiens

<400> 3

atggagctgg cggccttgtg ccgctggggg ctctcctcgc cctctttgcc ccccgagacc
60

gcgagcaccg aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccag 1
20

acccacctgg acatgctccg ccacctctac cagggttgcc aggtggtgca gggaaacctg 1
80

gaactcacct acctgcccac caatgccagc ctgtccttcc tgcaggatat ccaggagggtg 2
40

cagggtctacg tgctcatcgc tcacaaccaa gtgaggcagg tcccactgca gaggctgcgg 3
00

attgtgcgag gcaccagct ctttgaggac aactatgccc tggccgtgct agacaatgga 3
60

gacccgctga acaataccac cctgtcaca ggggcctccc caggaggcct gcgggagctg 4
20

cagcttcgaa gcctcacaga gatcttgaaa ggaggggtct tgatccagcg gaacccccag 4
80

ctctgctacc aggacacgat tttgtggaag gacatcttcc acaagaacaa ccagctggct 5
40

ctcacactga tagacaccaa ccgctctcgg gcctgccacc cctgttctcc gatgtgtaag 6
00

ggctcccgtc gctggggaga gagttctgag gattgtcaga gcctgacgcg cactgtctgt 6
60

gccggtggct gtgcccgtg caaggggcca ctgcccactg actgctgcca tgagcagtgt 7

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
20

gctgccggct gcacgggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 80	7
agtggcatct gtgagctgca ctgcccagcc ctggtcacct acaacacaga cacgtttgag 40	8
tccatgcccc atcccagagg ccggtataca ttccggcgcca gctgtgtgac tgccctgtccc 00	9
tacaactacc tttctacgga cgtgggatcc tgcaccctcg tctgccccct gcacaaccaa 60	9
gaggtgacag cagaggatgg aacacagcgg tgtgagaagt gcagcaagcc ctgtgcccga 20	10
gtgtgctatg gtctgggcat ggagcacttg cgagagggtga gggcagttac cagtgccaat 80	10
atccaggagt ttgctggctg caagaagatc tttgggagcc tggcatttct gccggagagc 40	11
tttgatgggg acccagcctc caacactgcc ccgctccagc cagagcagct ccaagtgttt 00	12
gagactctgg aagagatcac aggttaccta tacatctcag catggccgga cagcctgcct 60	12
gacctcagcg tcttccagaa cctgcaagta atccggggac gaattctgca caatggcgcc 20	13
tactcgctga ccctgcaagg gctgggcatc agctggctgg ggctgcgctc actgagggaa 80	13
ctgggcagtg gactggccct catccaccat aacacccacc tctgcttcgt gcacacgggtg 40	14
ccctgggacc agctcttttcg gaaccgcac caagctctgc tccacactgc caaccggcca 00	15
gaggacgagt gtgtgggcca gggcctggcc tgccaccagc tgtgcgcccg agggcactgc 60	15
tggggtccag ggcccacca gtgtgtcaac tgcagccagt tccttcgggg ccaggagtgc 20	16
gtggaggaat gccgagtact gcaggggctc cccaggagat atgtgaatgc caggcactgt 60	16

'ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
80

ttgccgtgcc accctgagtg tcagccccag aatggctcag tgacctgttt tggaccggag 17
40

gctgaccagt gtgtggcctg tgcccactat aaggaccctc ccttctgcgt ggcccgtgc 18
00

cccagcggtg tgaaacctga cctctcctac atgcccatct ggaagtttcc agatgaggag 18
60

ggcgcatgcc agccttgccc catcaactgc acccactcct gtgtggacct ggatgacaag 19
20

ggctgccccg ccgagcagag agccagccct ctgacgtcca tcgtctctgc ggtggttggc 19
80

attctgctgg tcgtggtctt gggggtggtc tttgggatcc tcatcaagcg acggcagcag 20
40

aagatccgga agtacacgat gcggagactg ctgcaggaaa cggagctggt ggagccgctg 21
00

acacctagcg gagcgatgcc caaccaggcg cagatgcgga tcctgaaaga gacggagctg 21
60

aggaaggtga aggtgcttgg atctggcgct tttggcacag tctacaaggg catctggatc 22
20

cctgatgggg agaattgtgaa aattccagtg gccatcaaag tgttgaggga aaacacatcc 22
80

cccaaagcca acaaagaaat cttagacgaa gcatacgtga tggctggtgt gggctcccca 23
40

tatgtctccc gccttctggg catctgcctg acatccacgg tgcagctggt gacacagctt 24
00

atgccctatg gctgcctctt agaccatgtc cgggaaaacc gcggacgcct gggctcccag 24
60

gacctgctga actggtgtat gcagattgcc aaggggatga gctacctgga ggatgtgcgg 25
20

ctcgtacaca gggacttggc cgctcggaac gtgctggtca agagtcccaa ccatgtcaaa 25
80

attacagact tcgggctggc tcggctgctg gacattgacg agacagagta ccatgcagat 26

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
40

gggggcaagg tgcccatcaa gtggatggcg ctggagtcca ttctccgccg gcggttcacc 27
00

caccagagtg atgtgtggag ttatggtgtg actgtgtggg agctgatgac ttttggggcc 27
60

aaaccttacg atgggatccc agcccgggag atccctgacc tgctggaaaa gggggagcgg 28
20

ctgccccagc ccccatctg caccattgat gtctacatga tcatggtcaa atgttggtatg 28
80

attgactctg aatgtcggcc aagattccgg gagttggtgt ctgaattctc ccgcatggcc 29
40

agggaccccc agcgctttgt ggtcatccag aatgaggact tgggcccagc cagtcccttg 30
00

gacagcacct tctaccgctc actgctggag gacgatgaca tgggggacct ggtggatgct 30
60

gaggagtatc tggtagccca gcagggcttc ttctgtccag accctgcccc gggcgctggg 31
20

ggcatggtcc accacaggca ccgcagctca tctaccagga gtggcggtgg ggacctgaca 31
80

ctagggctgg agccctctga agaggaggcc ccaggtctc cactggcacc ctccgaaggg 32
40

gctggctccg atgtatttga tggtagacctg ggaatggggg cagccaaggg gctgcaaagc 33
00

ctccccacac atgaccccag ccctctacag cgttacagtg aggacccac agtacccttg 33
60

ccctctgaga ctgatggcta cgttgcccc ctgacctgca gccccagcc tgaatatgtg 34
20

aaccagccag atgttcggcc ccagccccct tcgccccgag agggccctct gcctgctgcc 34
80

cgacctgctg gtgccactct ggaaagggcc aagactctct cccagggaa gaatggggtc 35
40

gtcaaagacg tttttgcctt tgggggtgcc gtggagaacc ccgagtactt gacacccag 36

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
00

ggaggagctg cccctcagcc ccaccctcct cctgccttca gccagcctt cgacaacctc 36
60

tattactggg accaggaccc accagagcgg ggggctccac ccagcacctt caaagggaca 37
20

cctacggcag agaaccaga gtacctgggt ctggacgtgc cagtgtga 37
68

<210> 4

<211> 3429

<212> DNA

<213> Homo sapiens

<400> 4

atggctttct gtgctaaaat gaggagctcc aagaagactg aggtgaacct ggaggccctc
60

gagccagggg tggaagtgat cttctatctg tcggacaggg agcccctccg gctgggcagt 1
20

ggagagtaca cagcagagga actgtgcac agggctgcac aggcattgcc tatctctcct 1
80

ctttgtcaca acctctttgc cctgtatgac gagaacacca agctctggta tgctccaaat 2
40

cgcaccatca ccgttgatga caagatgtcc ctccggctcc actaccggat gaggttctat 3
00

ttcaccaatt ggcatggaac caacgacaat gaggagtcag tgtggcgtca ttctccaaag 3
60

aagcagaaaa atggctacga gaaaaaaaaag attccagatg caaccctctc ccttgatgcc 4
20

agctcactgg agtatctgtt tgctcaggga cagtatgatt tgggtgaaatg cctggctcct 4
80

attcgagacc ccaagaccga gcaggatgga catgatattg agaacgagtg tctagggatg 5
40

gctgtcctgg ccattctcaca ctatgccatg atgaagaaga tgcagttgcc agaactgccc 6
00

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
aaggacatca gctacaagcg atatattcca gaaacattga ataagtccat cagacagagg 6
60

aacctttctca ccaggatgcg gataaataat gttttcaagg atttcctaaa ggaatttaac 7
20

aacaagacca tttgtgacag cagcgtgtcc acgcatgacc tgaaggtgaa atacttggct 7
80

accttggaac ctttgacaaa acattacggt gctgaaatat ttgagacttc catgttactg 8
40

atttcatcag aaaatgagat gaattgggtt cattcgaatg acggtggaaa cgttctctac 9
00

tacgaagtga tgggtgactgg gaatcttggga atccagtggga ggcataaacc aaatgttgtt 9
60

tctgttgaaa aggaaaaaaaa taaactgaag cggaaaaaac tggaaaataa agacaagaag 10
20

gatgaggaga aaaacaagat ccgggaagag tggacaatt tttcattctt ccctgaaatc 10
80

actcacattg taataaagga gtctgtggtc agcattaaca agcaggacaa caagaaaatg 11
40

gaactgaagc tctcttccca cgaggaggcc ttgtcctttg tgtccctggg agatggctac 12
00

ttccggctca cagcagatgc ccatcattac ctctgcaccg acgtggcccc cccgttgatc 12
60

gtccacaaca tacagaatgg ctgtcatggg ccaatctgta cagaatacgc catcaataaa 13
20

ttgcggcaag aaggaagcga ggaggggatg tacgtgctga ggtggagctg caccgacttt 13
80

gacaacatcc tcatgaccgt caccgtgctt gagaagtctg agcaggtgca ggggtgccag 14
40

aagcagttca agaactttca gatcgagggtg cagaagggcc gctacagtct gcacgggttcg 15
00

gaccgcagct tccccagctt gggagacctc atgagccacc tcaagaagca gatcctgcgc 15
60

CENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

acggataaca tcagcttcat gctaaaacgc tgctgccagc ccaagccccg agaaatctcc 16
20

aacctgctgg tggctactaa gaaagcccag gagtggcagc ccgtctaccc catgagccag 16
80

ctgagtttcg atcggatcct caagaaggat ctggtgcagg gcgagcacct tgggagaggc 17
40

acgagaacac acatctattc tgggaccctg atggattaca aggatgacga aggaacttct 18
00

gaagagaaga agataaaaagt gatcctcaaa gtcttagacc ccagccacag ggataatttc 18
60

ctggccttct tcgaggcagc cagcatgatg agacaggctc cccacaaaca catcgtgtac 19
20

ctctatggcg tctgtgtccg cgacgtggag aatatcatgg tggagaggtt tgtggaaggg 19
80

ggtcctctgg atctcttcat gcaccggaaa agtgatgtcc ttaccacacc atggaaattc 20
40

aaagttgcca aacagctggc cagtgccctg agctacttgg aggataaaga cctggtccat 21
00

ggaaatgtgt gtactaaaaa cctcctcctg gcccgtaggg gaatcgacag tgagtgtggc 21
60

ccattcatca agctcagtga ccccgcatc cccattacgg tgctgtctag gcaagaatgc 22
20

attgaacgaa tcccatggat tgctcctgag tgtgttgagg actccaagaa cctgagtgtg 22
80

gctgctgaca agtggagctt tggaaccacg ctctgggaaa tctgctacaa tggcgagatc 23
40

cccttgaaag acaagacgct gattgagaaa gagagattct atgaaagccg gtgcaggcca 24
00

gtgacaccat catgtaagga gctggctgac ctcatgaccc gctgcatgaa ctatgacccc 24
60

aatcagaggc ctttcttccg agccatcatg agagacatta ataagcttga agagcagaat 25
20

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
ccagatattg tttccagaaa aaaaaaccag ccaactgaag tggacccac acattttgag 25
80

aagcgcttcc taaagaggat ccgtgacttg ggagagggcc actttgggaa ggttgagctc 26
40

tgcaggatg accccgaaga caatacaggg gagcagggtg ctgttaaadc tctgaagcct 27
00

gagagtggag gtaaccacat agctgatctg aaaaaggaaa tcgagatctt aaggaacctc 27
60

tatcatgaga acattgtgaa gtacaaagga atctgcacag aagacggagg aaatgggtatt 28
20

aagctcatca tggaatttct gccttcggga agccttaagg aatatcttcc aaagaataag 28
80

aacaaaataa acctcaaaca gcagctaaaa tatgccgttc agatttgtaa ggggatggac 29
40

tatttgggtt ctcggaata cgttcaccgg gacttggcag caagaaatgt ccttgttgag 30
00

agtgaacacc aagtgaaaat tggagacttc ggtttaacca aagcaattga aaccgataag 30
60

gagtattaca ccgtcaagga tgaccgggac agccctgtgt tttgggtatgc tccagaatgt 31
20

ttaatgcaat ctaaatttta tattgcctct gacgtctggt cttttggagt cactctgcat 31
80

gagctgctga cttactgtga ttcagattct agtcccatgg ctttgttcct gaaaatgata 32
40

ggcccaaccc atggccagat gacagtcaca agacttgtga atacgttaaa agaaggaaaa 33
00

cgctgccgt gccaccta ctgtccagat gaggtttatc agcttatgag aaaatgctgg 33
60

gaattccaac catccaatcg gacaagcttt cagaacctta ttgaaggatt tgaagcactt 34
20

ttaaaataa 34
29

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

<210> 5
 <211> 3399
 <212> DNA
 <213> Homo sapiens

<400> 5
 atgggaatgg cctgccttac gatgacagaa atggagggaa catccacctc ttctatatat
 60
 cagaatggtg atatttcttg aaatgccaat tctatgaagc aaataga'cc agttcttcag 1
 20
 gtgtatcttt accattccct tgggaaatct gaggcagatt atctgacott tccatctggg 1
 80
 gagtatgttg cagaagaaat ctgtattgct gcttctaaag cttgtggtat cacacctgtg 2
 40
 tatcataata tgtttgcttt aatgagtga acagaaagga tctggtatcc acccaaccat 3
 00
 gtcttccata tagatgagtc aaccaggcat aatgtactct acagaataag attttacttt 3
 60
 cctcgttggg attgcagtgg cagcaacaga goctatcggc atggaatatc tcgaggtgct 4
 20
 gaagctctc ttcttgatga ctttgtcatg tcttacctct ttgctcagtg gcggcatgat 4
 80
 tttgtgcacg gatggataaa agtacctgtg actcatgaaa cacaggaaga atgtcttggg 5
 40
 atggcagtgt tagatatgat gagaatagcc aaagaaaacg atcaaacccc actggccatc 6
 00
 tataactcta tcagctacaa gacattctta ccaaaatgta ttcgagcaaa gatccaagac 6
 60
 tatcatatth tgacaaggaa gcgaataagg tacagatttc gcagatttat tcagcaattc 7
 20
 agccaatgca aagccactgc cagaaacttg aaacttaagt atcttataaa tctggaaact 7
 80
 ctgcagtctg ccttctacac agagaaatth gaagtaaaag aacctggaag tggtccttca 8
 40

INT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ggtgaggaga tttttgcaac cattataata actggaaacg gtggaattca gtggtcaaga 9
 00
 gggaaacata aagaaagtga gacactgaca gaacaggatt tacagttata ttgcgatttt 9
 60
 cctaataatta ttgatgtcag tattaagcaa gcaaaccaag aggggttcaaa tgaaagccga 10
 20
 gttgtaacta tccataagca agatggtaaa aatctggaaa ttgaaacttag ctcattaagg 10
 80
 gaagctttgt ctttcgtgtc attaattgat ggatattata gattaactgc agatgcacat 11
 40
 cattacctct gtaaagaagt agcacctcca gccgtgcttg aaaatataca aagcaactgt 12
 00
 catggcccaa tttcgatgga ttttgccatt agtaaactga agaaagcagg taatcagact 12
 60
 ggactgtatg tacttcgatg cagtcctaag gactttaata aatatttttt gacttttgct 13
 20
 gtcgagcgag aaaatgtcat tgaatataaa cactgtttga ttacaaaaaa tgagaatgaa 13
 80
 gagtacaacc tcagtgggac aaagaagaac ttcagcagtc ttaaagatct tttgaattgt 14
 40
 taccagatgg aaactgttcg ctgagacaat ataattttcc agtttactaa atgctgtccc 15
 00
 ccaaagccaa aagataaatc aaacottcta gtottcagaa cgaatgggtgt ttctgatgta 15
 60
 ccaacctcac caacattaca gaggcctact catatgaacc aaatgggtgtt tcacaaaatc 16
 20
 agaaatgaag atttgatatt taatgaaagc cttggccaag gcactttttac aaagattttt 16
 80
 aaaggcgtac gaagagaagt aggagactac ggtcaactgc atgaaacaga agttctttta 17
 40
 aaagttctgg ataaagcaca cagaaactat tcagagtctt tctttgaagc agcaagtatg 18
 00

INT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

atgagcaagc tttctcacia gcatttggtt ttaaattatg gagtatgtgt ctgtggagac 18
60

gagaatattc tggttcagga gtttgtaaaa tttggatcac tagatacata tctgaaaaag 19
20

aataaaaatt gtataaatat attatggaaa cttgaagttg ctaaacagtt ggcattgggcc 19
80

atgcattttc tagaagaaaa cacccttatt catgggaatg tatgtgcdaa aaatattctg 20
40

cttatcagag aagaagacag gaagacagga aatcctcctt tcatcaaact tagtgatcct 21
00

ggcattagta ttacagtttt gccaaaggac attcttcagg agagaatacc atgggtacca 21
60

cctgaatgca ttgaaaatcc taaaaattta aatttggcaa cagacaaatg gagttttggt 22
20

accactttgt gggaaatctg cagtggagga gataaacctc taagtgtctt ggattctcaa 22
80

agaaagctac aattttatga agataggcat cagcttcctg caccaaagtg ggcagaatta 23
40

gcaaacctta taaataattg tatggattat gaaccagatt tcaggccttc ttccagagcc 24
00

atcatacgag atcttaacag tttgtttact ccagattatg aactattaac agaaaatgac 24
60

atgttaccaa atatgaggat aggtgcccta gggttttctg gtgcctttga agaccgggat 25
20

cctacacagt ttgaagagag acatttgaaa tttctacagc aacttggcaa gggtaatttt 25
80

gggagtgtgg agatgtgccg gtatgacct ctacaggaca aactgggga ggtggtcgct 26
40

gtaaaaaagc ttccagcatag tactgaagag cacctaagag actttgaaag ggaaattgaa 27
00

atcctgaaat ccctacagca tgacaacatt gtaaagtaca agggagtgtg ctacagtgtc 27
60

INT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ggtcggcgta atctaaaatt aattatggaa tatttaccat atggaagttt acgagactat 28
20

cttcaaaaac ataaagaacg gatagatcac ataaaacttc tgcagtacac atctcagata 28
80

tgcaagggta tggagtatct tggtaaaaa aggtatatcc acagggatct ggcaacgaga 29
40

aatatattgg tggagaacga gaacagagtt aaaattggag attttggdtt aaccaaagtc 30
00

ttgccacaag acaaagaata ctataaagta aaagaacctg gtgaaagtcc catattctgg 30
60

tatgctccag aatcactgac agagagcaag ttttctgtgg cctcagatgt ttggagcttt 31
20

ggagtgggttc tgtatgaact tttcacatac attgagaaga gtaaaagtcc accagcggaa 31
80

tttatgcgta tgattggcaa tgacaaacaa ggacagatga tcgtgttcca tttgatagaa 32
40

cttttgaaga ataatggaag attaccaaga ccagatggat gccagatga gatctatatg 33
00

atcatgacag aatgctggaa caataatgta aatcaacgcc cctcctttag ggatctagct 33
60

cttcgagtgg atcaaataag ggataacatg gctggatga 33
99

<210> 6
<211> 1584
<212> DNA
<213> Homo sapiens

<400> 6
atggcggggc gaggtctctt ggtttcctgg cgggcatttc acggctgtga ttctgctgag
60

gaacttcccc gggtagagccc ccgcttcctc cgagcctggc accccctcc cgtctcagcc 1
20

aggatgccaa cgaggcgctg ggccccgggc acccagtgtg tcaccaaatg cgagcacacc 1

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
80

cgccccaagc caggggagct ggccttcgc aagggcgacg tggtcacat cctggaggcc	2
40	
tgcgagaaca agagctggta ccgctcaag caccacacca gtggacagga ggggctgctg	3
00	
gcagctgggg cgctgcggga cggggaggcc ctctccgcag accccaagct cagcctcatg	3
60	
ccgtggttcc acgggaagat ctggggccag gaggctgtcc agcagctgca gcctcccag	4
20	
gatgggctgt tcttggtgcg ggagtcgcg cgccaccccg gcgactacgt cctgtgcgtg	4
80	
agctttggcc gcgacgtcat ccactaccgc gtgctgcacc gcgacggcca cctcacaatc	5
40	
gatgaggccg tgttcttctg caacctcatg gacatggtgg agcattacag caaggacaag	6
00	
ggcgctatct gcaccaagct ggtgagacca aagcggaaac acgggaccaa gtcggccgag	6
60	
gaggagctgg ccagggcggg ctggttactg aacctgcagc atttgacatt gggagcacag	7
20	
atcgagagg gagagtttgg agctgtcctg cagggtgagt acctggggca aaaggtggcc	7
80	
gtgaagaata tcaagtgtga tgtgacagcc caggccttcc tggacgagac ggccgtcatg	8
40	
acgaagatgc aacacgagaa cctggtgcgt ctctggggcg tgatcctgca ccaggggctg	9
00	
tacattgtca tggagcacgt gagcaagggc aacctggtga actttctgcg gacccggggt	9
60	
cgagccctcg tgaacaccgc tcagctcctg cagttttctc tgcacgtggc cgagggcatg	10
20	
gagtacctgg agagcaagaa gcttgtgcac cgcgacctgg ccgcccgcaa catcctggtc	10
80	
tcagaggacc tggtgccaa ggtcagcgac ttggccctgg ccaaagccga gcggaagggg	11

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
40

ctagactcaa gccggctgcc cgtcaagtgg acggcgcccg aggctctcaa acacgggttc 12
00

accagcaagt cggatgtctg gagttttggg gtgctgctct gggaggtctt ctcatatgga 12
60

cgggctccgt accctaaaat gtcactgaaa gaggtgtcgg aggccgtgga gaaggggtac 13
20

cgcatggaac cccccgaggg ctgtccaggg cccgtgcacg tcctcatgag cagctgctgg 13
80

gaggcagagc cgcccgccgg ccacccttcc gcaaaactggc cgagaagctg gcccgggagc 14
40

tacgcagtgc aggtgccccca gcctccgtct cagggcagga cgccgacggt ccacctcgcc 15
00

ccgaagccag gagccctgac cccaccgggt ggcccttggc cccagaggac cgagagagtg 15
60

gagagtgcgg cgtgggggca ctga 15
84

<210> 7

<211> 2544

<212> DNA

<213> Homo sapiens

<400> 7

atggagccct tgaagagcct cttcctcaag agccctctag ggtcatggaa tggcagtggc 60

agcgggggtg gtgggggagg tggaggaggc cggcctgagg ggtctccaaa ggcagcgggt 1
20

tatgccaacc cgggtgtggac agccctgttc gactacgagc ccagtgggca ggatgagctg 1
80

gccctgagga agggtgaccg tgtggagggt ctgtcccggg acgcagccat ctcaggagac 2
40

gagggctggt gggcgggcca ggtgggtggc caggtgggca tcttcccgtc caactatgtg 3
00

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 tctcggggtg gcggcccgcc cccctgcgag gtggccagct tccaggagct gcggctggag 3
 60
 gaggtgatcg gcattggagg ctttggcaag gtgtacaggg gcagctggcg aggtgagctg 4
 20
 gtggctgtga aggcagctcg ccaggacccc gatgaggaca tcagtgtgac agccgagagc 4
 80
 gttcgccagg agggccggct cttcgccatg ctggcacacc ccaacatcat tgccctcaag 5
 40
 gctgtgtgcc tggaggagcc caacctgtgc ctggtgatgg agtatgcagc cgggtgggccc 6
 00
 ctcagccgag ctctggccgg gcggcgcgctg cctccccatg tgctggtcaa ctgggctgtg 6
 60
 cagattgccc gtgggatgca ctacctgcac tgcgaggccc tgggtgcccgat catccaccgt 7
 20
 gatctcaagt ccaacaacat tttgctgctg cagcccattg agagtgcaga catggagcac 7
 80
 aagaccctga agatcaccga ctttggcctg gcccagagagt ggcacaaaac cacacaaatg 8
 40
 agtgccgcgg gcacctacgc ctggatggct cctgagggtta tcaaggcctc caccttctct 9
 00
 aagggcagtg acgtctggag ttttgggggtg ctgctgtggg aactgctgac cggggagggtg 9
 60
 ccataccgtg gcattgactg ccttgctgtg gcctatggcg tagctgttaa caagctcaca 10
 20
 ctgcccattc catccacctg ccccgagccc ttgcacagc ttatggccga ctgctgggcg 10
 80
 caggaccccc accgcaggcc cgacttcgcc tccatcctgc agcagttgga ggcgctggag 11
 40
 gcacaggtcc tacgggaaat gccgcgggac tccttcatt ccattgcagga aggctggaag 12
 00
 cgcgagatcc agggctctct cgacgagctg cgagccaagg aaaaggaact actgagccgc 12
 60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
gaggaggagc tgacgcgagc ggcgcgcgag cagcggtcac aggcggagca gctgcggcgg 13
20

cgcgagcacc tgctggccca gtgggagcta gaggtgttcg agcgcgagct gacgctgctg 13
80

ctgcagcagg tggaccgcga ggcaccgcac gtgcgcgcgc gccgcgggac attcaagcgc 14
40

agcaagctcc gggcgcgca cggcggcgag cgtatcagca tgccactcga cttcaagcac 15
00

cgcatcaccg tgcaggcctc acccggcctt gaccggagga gaaacgtctt cgaggctcggg 15
60

cctggggatt cgcccacctt tccccggttc cgagccatcc agttggagcc tgcagagcca 16
20

ggccaggcat ggggccgcca gtccccccga cgtctggagg actcaagcaa tggagagcgg 16
80

cgagcatgct gggcttgggg tcccagttcc cccaagcctg gggaagccca gaatgggagg 17
40

agaaggtccc gcatggacga agccacatgg tacctggatt cagatgactc atccccctta 18
00

ggatctcctt ccacaccccc agcactcaat ggtaaccccc cgcggcctag cctggagccc 18
60

gaggagccca agaggcctgt cccgcgagag cgcggtagca gctctgggac gccaagctg 19
20

atccagcggg cgctgctgcg cggcaccgcc ctgctgcct cgctgggcct tggccgcgac 19
80

ctgcagccgc cgggaggccc aggacgcgag cgcggggagt ccccgacaac accccccacg 20
40

ccaacgcccg cgccctgccc gaccgagccg ccccttccc cgctcatctg cttctcgtc 21
00

aagacgcccg actccccgcc cactcctgca cccctgttgc tggacctggg tatccctgtg 21
60

ggccagcggg cagccaagag ccccgacgt gaggaggagc cccgcggagg cactgtctca 22
20

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 cccccaccgg ggacatcacg ctctgctcct ggcacccag gcacccacg ttcaccacc 22
 80

ctgggcctca tcagccgacc toggccctcg ccccttcgca gccgcattga tccctggagc 23
 40

tttgtgtcag ctggggccacg gccttctccc ctgccatcac cacagcctgc acccgccga 24
 00

gcaccctgga ccttggtccc ggactcagac ccttcttggg actccccacc tgccaacccc 24
 60

ttccaggggg gccccagga ctgcagggca cagaccaaag acatgggtgc ccaggccccg 25
 20

tgggtgccgg aagcggggcc ttga 25
 44

<210> 8

<211> 2640

<212> DNA

<213> Homo sapiens

<400> 8

atgagtgatt actgggttgt tggaaagaag tctaactatg aagtattaga aaaagatgtt
 60

ggtttaaagc gattttttcc taagagtta ctggattctg tcaaggccaa aacactaaga 1
 20

aaactgatcc aacaaacatt tagacaattt gccaacctta atagagaaga aagtattctg 1
 80

aaattctttg agatcctgtc tccagtctac agatttgata aggaatgctt caagtgtgct 2
 40

cttggttcaa gctggattat ttcagtggaa ctggcaatcg gccagaaga aggaatcagt 3
 00

tacctaacgg acaagggtg caatcccaca catcttgctg acttcactca agtgcaaacc 3
 60

attcagtatt caaacagtga agacaaggac agaaaaggaa tgctacaact aaaaatagca 4
 20

ggtgcacccg agcctctgac agtgacggca ccattccctaa ccattgcgga gaatatggct 4
 80

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gacctaataag atgggtactg cgggctgggtg aatggaacct cgcagtcatt tatcatcaga 5
 40
 cctcagaaaag aaggtgaacg ggcttttgcca tcaataccaa agttggccaa cagcgaaaag 6
 00
 caaggcatgc ggacacacgc cgtctctgtg tcagaaacag atgattatgc tgagattata 6
 60
 gatgaagaag atacttacac catgccctca accagggatt atgagattca aagagaaaga 7
 20
 atagaacttg gacgatgtat tggagaaggc caatttggag atgtacatca aggcatttat 7
 80
 atgagtccag agaatccagc tttggcgggt gcaattaaaa catgtaaaaa ctgtacttcg 8
 40
 gacagcgtga gagagaaatt tcttcaagaa gcctgccatt acacatcttt gcaactggaat 9
 00
 tgggtgcagat atataagtga tcctaattgt gatgcctgcc cagaccccag gaatgcagag 9
 60
 ttaacaatgc gtcagtttga ccacctcat attgtgaagc tgattggagt catcacagag 10
 20
 aatcctgtct ggataatcat ggagctgtgc acacttggag agctgaggtc atttttgcaa 10
 80
 gtaaggaaat acagtttgga tctagcatct ttgatcctgt atgcctatca gcttagtaca 11
 40
 gctcttgcac atctagagag caaaagatct gtacacaggg acattgctgc tcggaatggt 12
 00
 ctggtgtcct caaatgattg tgtaaaatta ggagactttg gattatcccg atatatggaa 12
 60
 gatagtactt actacaaagc ttccaaagga aaattgccta ttaaattggat ggctccagag 13
 20
 tcaatcaatt ttcgacgttt tacctcagct agtgacgtat ggatgttttg tgtgtgtatg 13
 80
 tgggagatac tgatgcatgg tgtgaagcct tttcaaggag tgaagaacaa tgatgtaatc 14
 40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

```

ggtcgaattg aaaatgggga aagattacca atgcctccaa attgtcctcc taccctctac   15
00

agccttatga cgaaatgctg ggcctatgac cccagcaggc ggcccaggtt tactgaactt   15
60

aaagctcagc tcagcacaat cctggaggaa gagaaggctc agcaagaaga gcgcatgagg   16
20

atggagtcca gaagacaggc cacagtgtcc tgggactccg gagggctctga tgaagcaccg   16
80

cccaagccca gcagaccggg ttatcccagt ccgaggtcca gcgaaggatt ttatcccagc   17
40

ccacagcaca tgggtacaaac caatcattac caggtttctg gctaccctgg ttcacatgga   18
00

atcacagcca tggctggcag catctatcca ggtcaggcat ctcttttggg ccaaacagat   18
60

tcatggaatc atagatctca ggagatagca atgtggcagc ccaatgtgga ggactctaca   19
20

gtattggacc tgcgagggat tgggcaagtg ttgccaaacc atctgatgga agagcgtcta   19
80

atccgacagc aacaggaaat ggaagaagat cagcgctggc tggaaaaaga ggaaagattt   20
40

ctgattggaa accaacatat atatcagcct gtgggtaaac cagatcctgc agctccacca   21
00

aagaaaccgc ctgcccctgg agctcccggg catctgggaa gccttgccag cctcagcagc   21
60

cctgctgaca gctacaacga ggggtgtcaag cttcagcccc aggaaatcag cccccctcct   22
20

actgccaacc tggaccggtc gaatgataag gtgtacgaga atgtgacggg cctggtgaaa   22
80

gctgtcatcg agatgtccag taaaatccag ccagccccac cagaggagta tgtccctatg   23
40

gtgaaggaag tcggcttggc cctgaggaca ttattggcca ctgtggatga gaccattccc   24
00

```

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ctcctaccag ccagcaccca ccgagagatt gagatggcac agaagctatt gaactctgac 24
60

ctgggtgagc tcatacaaa gatgaaactg gccagcagt atgtcatgac cagcctccag 25
20

caagagtaca aaaagcaaat gctgactgcc gctcacgcc tggctgtgga tgcaaaaac 25
80

ttactcgatg tcattgacca agcaagactg aaaatgcttg ggcagacgag accacactga 26
40

<210> 9
<211> 3213
<212> DNA
<213> Homo sapiens

<400> 9
atgggagctg cgcggggac cccggccaga ccccgccggt tgcctctgct cagcgtcctg
60

ctgctgccgc tgctgggagg taccagaca gccattgtct tcataagca gccgtcctcc 1
20

caggatgcac tgcaggggag ccggggcgtg cttcgtcttg aggttgaggc tccgggcccg 1
80

gtacatgtgt actggctgct cgatggggcc cctgtccagg acacggagcg gcgtttcgcc 2
40

cagggcagca gcctgagctt tgcagctgtg gaccggctgc aggactctgg caccttcag 3
00

tgtgtggctc gggatgatgt cactggagaa gaagcccgca gtgccaacgc ctcttcaac 3
60

atcaaattga ttgaggcagg tcctgtggtc ctgaagcatc cagcctcgga agctgagatc 4
20

cagccacaga ccaggtcac acttcgttgc cacattgatg ggcacccctg gccacctac 4
80

caatggttcc gagatgggac cccctttct gatggtcaga gcaaccacac agtcagcagc 5
40

aaggagcggg acctgacgct ccggccagct ggtcctgagc atagtgggct gtattcctgc 6

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
00

tgcgcccaca gtgcttttgg ccaggcttgc agcagccaga acttcacctt gagcattgct	6
60	
gatgaaagct ttgccagggg ggtgctggca cccaggacg tggtagtagc gaggtatgag	7
20	
gaggccatgt tccattgccca gttctcagcc cagccacccc cgagcctgca gtggctcttt	7
80	
gaggatgaga ctcccatcac taaccgcagt cgtccccac acctccgcag agccacagtg	8
40	
tttgccaacg ggtctctgct gctgaccag gtccggccac gcaatgcagg gatctaccgc	9
00	
tgcattggcc aggggcagag gggcccaccc atcatcctgg aagccacact tcacctagca	9
60	
gagattgaag acatgccgct atttgagcca cgggtgttta cagctggcag cgaggagcgt	10
20	
gtgacctgcc ttcccccaa gggctctgcc gagcccagcg tgtggtggga gcacgcggga	10
80	
gtccggctgc ccacccatgg cagggctctac cagaagggcc acgagctggg gttggccaat	11
40	
attgctgaaa gtgatgctgg tgtctacacc tgccacgcgg ccaacctggc tggtcagcgg	12
00	
agacaggatg tcaacatcac tgtggccact gtgccctcct ggctgaagaa gcccgaagac	12
60	
agccagctgg aggagggcaa acccggctac ttggattgcc tgaccaggc cacacaaaa	13
20	
cctacagttg tctggtacag aaaccagatg ctcatctcag aggactcacg gttcgaggtc	13
80	
ttcaagaatg ggaccttgcg catcaacagc gtggaggtgt atgatgggac atggtaccgt	14
40	
tgtatgagca gcaccccagc cggcagcatc gaggcgcaag cccgtgtcca agtgctggaa	15
00	
aagctcaagt tcacaccacc accccagcca cagcagtgca tggagtttga caaggaggcc	15

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
60

acggtgccct gttcagccac aggccgagag aagcccacta ttaagtggga acgggcagat 16
20

gggagcagcc tcccagagtg ggtgacagac aacgctggga ccctgcattt tgcccgggtg 16
80

actcgagatg acgctggcaa ctacacttgc attgcctcca acgggccgca gggccagatt 17
40

cgtgcccattg tccagctcac tgtggcagtt tttatcacct tcaaagtgga accagagcgt 18
00

acgactgtgt accagggcca cacagcccta ctgcagtgcg aggccaggg ggacccaag 18
60

ccgctgattc agtggaaagg caaggaccgc atcctggacc ccaccaagct gggaccag 19
20

atgcacatct tccagaatgg ctccctgggtg atccatgacg tggcccctga ggactcaggc 19
80

cgctacacct gcattgcagg caacagctgc aacatcaagc acacggaggc cccctctat 20
40

gtcgtggaca agcctgtgcc ggaggagtgc gagggccctg gcagccctcc cccctacaag 21
00

atgatccaga ccattgggtt gtcggtgggt gccgctgtgg cctacatcat tgccgtgctg 21
60

ggcctcatgt tctactgcaa gaagcgctgc aaagccaagc ggctgcagaa gcagcccag 22
20

ggcgaggagc cagagatgga atgcctcaac ggtgggcctt tgcagaacgg gcagccctca 22
80

gcagagatcc aagaagaagt ggccttgacc agcttgggtc ccggccccgc ggccaccaac 23
40

aaacgccaca gcacaagtga taagatgcac ttcccacggt ctagcctgca gcccatcacc 24
00

acgctgggga agagtgagtt tggggagggtg ttccctggcaa aggctcaggg cttggaggag 24
60

ggagtggcag agaccctggt acttgtgaag agcctgcaga gcaaggatga gcagcagcag 25

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
20

```

ctggacttcc ggagggagtt ggagatgttt gggaagctga accacgcaa cgtggtgcgg 25
80
ctcctggggc tgtgccggga ggctgagccc cactacatgg tgctggaata tgtggatctg 26
40
ggagacctca agcagttcct gaggatttcc aagagcaagg atgaaaaatt gaagtcacag 27
00
cccctcagca ccaagcagaa ggtggcccta tgcacccagg tagccctggg catggagcac 27
60
ctgtccaaca accgctttgt gcataaggac ttggctgcgc gtaactgcct ggtcagtgcc 28
20
cagagacaag tgaaggtgtc tgccctgggc ctgagcaagg atgtgtacaa cagtgagtac 28
80
taccacttcc gccaggcctg ggtgccgctg cgctggatgt ccccgaggc catcctggag 29
40
ggtgacttct ctaccaagtc tgatgtctgg gccttcggtg tgctgatgtg ggaagtgttt 30
00
acacatggag agatgcccc a tgggtgggcag gcagatgatg aagtactggc agatttgcag 30
60
gctgggaagg ctagacttcc tcagcccagag ggctgccctt ccaaactcta tcggctgatg 31
20
cagcgctgct gggccctcag cccaaggac cggccctcct tcagtgagat tgccagcgcc 31
80
ctgggagaca gcaccgtgga cagcaagccg tga 32
13

```

<210> 10
 <211> 3645
 <212> DNA
 <213> Caenorhabditis elegans

<400> 10
 atgggtcatt cacatagtagc tgggaaagaa atcaatgaca atgaactctt cacatgtgaa
 60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
gatcctgtat tcgatcaacc ggtggcgagt ccgaaatcgg agatttcgag caagttagcc 1

20

gaagaaatag aacggagcaa aagtccactc atactcgaga tgttccgtcc aacatttgac 1
80

acatttcgac cgccgaacag tgacagctcg actttccgtg gcagccagag cagagaggat 2
40

ctagtagcat gtagctcaat gaattcggta aacaacgtgc acgatatgaa tacagtttcc 3
00

tcttcatcat catcatctgc accacttttt gtagctctct atgatttcca cgggtgtcggc 3
60

gaagagcagc tttcgttacg aaagggatgat cagggtgcgaa ttctgggtta caacaaaaac 4
20

aatgagtggg gtgaggcacg attatactca acgagaaaaa atgatgagag caatcagcga 4
80

aggttaggcg aaattggatg ggtgcccaagt aattttattg ctccgtacaa ctctttggat 5
40

aagtacacgt ggtatcatgg caaaatctca aggagcgatt ctgaggctat actaggcagt 6
00

ggaatcactg gctcattttt ggtacgagaa agtgaaacaa gtataggaca gtatacaatc 6
60

tctgttcgcc atgatggctg agtgtttcac taccggatca atgtagataa tacagaaaag 7
20

atgttcatca cacaagaagt caaattccgc acacttggag agttagtga ccatcatagt 7
80

gttcacgctg atgggctgat atgtctttta atgtaccag cgagtaaaaa ggacaaggga 8
40

cgtggactgt tctcactgtc gcctaacgag ccagacgaat gggaactaga tagatccgaa 9
00

atcatcatgc ataacaaatt gggcggtgga cagtacggag acgtgtacga gggatactgg 9
60

aaacgacatg actgcacaat tgcagtgaaa gcgttgaagg aagatgcaat gccacttcat 10
20

INT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 gaatttttag cagaagctgc tatcatgaaa gatttgcacc acaaaaacct tgttcgactg 10
 80
 cttggagtat gcactcacga ggcaccgttc tatattatca ccgagtttat gtgcaatgga 11
 40
 aatttgctcg agtacctgag gaggaccgat aaaagcttgc tgccacctat aatccttggt 12
 00
 caaatggcta gtcagattgc gtccggcatg tcgtacctgg aagccagaca cttcattcat 12
 60
 agggatttgg ccgcaaggaa ttgcttagta tccgagcata atattgtaaa aattgccgac 13
 20
 tttgggttgg caagattcat gaaggaagac acctatacag cacatgctgg agccaagttt 13
 80
 cctatcaaat ggactgcccc agaggggctt gcattcaaca ccttcagctc taaatctgat 14
 40
 gtttgggcgt ttggagttct gctctgggaa attgccacgt atggaatggc tccctatcca 15
 00
 ggcgtcgagc tgtcaaatgt ttatgggctt ttggaaaacg ggttccgtat ggatggcccc 15
 60
 caagggtgcc ctccatcggg gtatcgccctt atgcttcagt gctggaactg gtctccgtcg 16
 20
 gatcgtcctc gtttccgaga tattcatttc aacttggaat atctaatttc aagcaattcc 16
 80
 ttgaacgacg aggtgcaaaa acaattgaaa aagaataatg ataagaaact ggaaagtgac 17
 40
 aaaagaaggt ctaacgttag agaacgaagt gactctaat ccagacattc ttcacatcac 18
 00
 gaccgtgacc gtgaccggga atctcttcat tctcggaact caaatcctga aattcccaat 18
 60
 agaagtttta taagaaccga cgacagtgtg tcattottca atccatcaac cacaagtaaa 19
 20
 gtaacgtcgt ttcgtgctca aggaccaccg tcccaccac cgccacaaca aaacacaaaa 19
 80

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 ccgaaactat tgaagtcagt tctgaatagt aacgctcgtc atgcatcaga ggagtttgag 20
 40

agaaacgaac aagatgacgt gggttcctttg gccgagaaaa atgtgcggaa agcggttacc 21
 00

aggctgggtg gaactatgcc gaaaggacaa aggatagatg catattttaga ctcgatgaga 21
 60

agggttgaca gttggaaaga aagcactgac gctgacaatg aaggggcggg atcatcatcg 22
 20

ctgagcagaa ctgtatcgaa tgattctctt gacacacttc ctctgccaga ttctatgaac 22
 80

tcgagtacgt atgttaaaat gcatcctgca tccggcgaga acgttttcct gagacaaatt 23
 40

cgttcaaaac tgaagaaacg aagtgcgaca ccagagttgg atcatattga ttcagatact 24
 00

gccgatgaaa caacaaaatc ggaaaagtca ccctttggat ctttgaataa atcttctatc 24
 60

aaatatccaa ttaaaaacgc gcccgattt agtgagaatc actctagagt cagccctgtc 25
 20

ccggtgccac catctcgtaa cgcttctgta agtgtaagac cggattcgaa agcagaagac 25
 80

tcacgcgatg agacaacaaa agatgttgga atgtggggtc ctaagcatgc cgtgacgcgg 26
 40

aaaattgaaa ttgtcaagaa tgattcgtat ccaaattgtg aaggcgagtt gaaagcaaaa 27
 00

attcgaaatt tacgtcatgt acccaaagaa gagagcaaca caagtagtca agaagatttg 27
 60

ccacttgatg cgacagacaa cacaaatgac agcatcattg tgattccaag agatgaaaaa 28
 20

gcaaaaagttc gtcaactggg gacacaaaaa gtatctcttc ttcaacatca tcggccattc 28
 80

tcactgcaat gtccaaacaa ttctacaagc tctgcaatat cgcattctga acacgcggat 29
 40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 agctcagaaa catcttcact ttccggtgtc tatgaggaac gtatgaaacc tgaacttcca 30
 00

agaaaacgga gtaatggcga tacaaaagtg gtgccagtaa catggattat caatggagaa 30
 60

aaggaacca atggtatggc tcgaacaaaa tctctacgtg atattacatc aaagttcgaa 31
 20

cagcttgga cagcttcac gattgaaagt aagattgaag aagccgtccc atatcgtgag 31
 80

catgcattgg aaaagaaagg aacttcaaaa cgattttcaa tgctggaagg aagtaatgag 32
 40

ttgaagcatg ttgtcccacc gcgtaaaaac cgaaaccaag acgaatctgg ctcaattgat 33
 00

gaagaaccag tgagcaagga catgattgta tcgttgctca aagtaatcca aaaggaattt 33
 60

gtgaatcttt tcaatttggc gagctcagag atcactgatg aaaaactaca acaatttcta 34
 20

ataatggctg ataatgtaca aaaacttcat tccacgtgtt ccgtctatgc agaacaaatc 34
 80

tcaccgcata gtaaatttcg gttcaaagaa ctcttttctc aacttgaaat ctacaatcga 35
 40

caaattaaat tttcccacaa ccctcgagcg aagccagttg atgacaaact taaaatggcg 36
 00

ttccaggact gtttcgacca aatcatgagg ctggtggatc gctga. 36
 45

<210> 11

<211> 3672

<212> DNA

<213> Caenorhabditis elegans

<400> 11

atggcaagca cgtcaggggc gcttgtcgac gacaacgtcc tcgaagtgct ccgcaaagca
 60

cagttggacg catttattag tcagtttgtc ttcttattca acgtcagaag gtttgatcac 1
 20

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ttttcacatg ttcgagataa agatatgctg gaaattggta tgcaacaagt tcaaattcgg 80	1
cagctccgag agcagattct caaaatgtcc agagaaatgt ggaatcggag tgatccgaag 40	2
caagtgtaca ttcaagccga tcagtcatg ccagcacaaa attcgattga cgagaaagca 00	3
ctgattccaa atgagcagat taaactgtac gagttgattg gcgagggctc ttttgctgtg 60	3
gtgaagcgtg gtacgtggac acagagcaat gggacgcatg tgaatgtcgc tgtcaaaatt 20	4
ctccgcgaca tttctccaaa tattatggat gatttgagag tggaagccag tcatttgctc 80	4
aagctccagc acccgctctt gattcgcctt tacggaattg ttgccagcc agcgatgatg 40	5
gtgtttgaac tctgtgaagg tggttcactg ctcgacagac tacgagatga caaaaaggca 00	6
attcttcttg tgtcacggct tcatgactat tgtatgcaaa ttgcaaggc tttgcagttt 60	6
ttggagtcaa aacactgtgt acacagagat gtggcagcaa ggaatatttt gttggctaga 20	7
gacgaaagga cagtcaagat ctgtgatttt ggactcatgc gagcactaaa agaaaatgag 80	7
caaatgtaca ctatggctcc aaaaaagaaa gtcccatttg cctgggtgcc tccggaagca 40	8
cttcgtcatc gcaagttctc tcatgcttcc gacgtctggt cgtacggagt caccatctgg 00	9
gaggtgttca catttggcga ggagccatgg gtcggctgtc gagccatcga tgtgctcaaa 60	9
aacattgacg ccggcgagag gctggagaag cccaagtact gctcggagcg aatttatcaa 20	10
atcatgaaga attgttgga attcaatccg gcagagcgat gcaaatttgg tgcaattcga 80	10

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gaggacttgg tggcggccat gtttttggat gcagtggcaa gggagacgta caactctatt 11
 40
 caaccgggog cactacaatt gacaaaaggg gatgaagttg ttgtggtgga gaacacaggc 12
 00
 caagactggg ttggtcagaa caagaagaac caaaagtttg gcacattccc ccgatcagtt 12
 60
 gtgtttgcgc agacgaacaa cgcggttgcg gcagcgacgg cggttacccc acagaaagtt 13
 20
 ccaacggcgc caacgatcag aattccaccg tcacacccac cccagcccc gctgaaacca 13
 80
 ttgaacaata atacgaaaac ttgctgaac gaccgcacgt caaaaatttc aatgcctgtg 14
 40
 gcaggttctt tcatccatac cggtcacgga gaccactag gaggccaatc atggggtaac 15
 00
 ccagctacga ttgcggacat gtatctcaag aatccagtga acggcgctcc attgtctagt 15
 60
 atgtcgagtg gtgcggaaat tatcgccagt aaggagttgc tcaccaatgg cggccggagc 16
 20
 acacaccaac ctgctgctcc atgcctgcc gtcattgtcca agattcgagg tctttcgctt 16
 80
 gatttgccag aatatgatga ttctgatcga gcattcgatg atgggttttc tccgtcgaag 17
 40
 atcgagctgc ccagagagtt ttgtggcaat gacagcgtaa tcagtgggtg gtcgaacagc 18
 00
 atcggttgg ctaacactta tgtcatggaa ccgccaagc aggcatttga tattcgagga 18
 60
 aatcgagtgc tcccgccaac gaacaaggcg cctgtgctca ttccaactaa cccggcgcca 19
 20
 agtgtcatct cgagcacagc ttctgcagga atcacacttt ctacgaacag ttctcagatg 19
 80
 ttaccagtc aagaccgcca ttgcaatatg cccgcaaatc ttttccccga gcttcaacac 20
 40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

cgccctcaatc aaggaagttc aacgggaaat ggcgtccgac ctccggccagc ttctctgatt 21
00

ggaattcaaa acaatgattt gagcatgctc aaccctcaac aaccagcgaa tattccgtgc 21
60

ctggttccaa ctccggctcc accagctcca gcacactttt ctcaaccggt gtcttcccag 22
20

agagttgcac aacaacaaca gaacactttg caaaaagcgc tgaacgatga actcaaagga 22
80

aatctgaaca aaagacctac tggcacgacg gcaccaccgt caaatgggtt caatgctcca 23
40

cgagcagacg ttgcaccggt ccaacagcga ccgatctcat cggcatctat tccagcgctc 24
00

caaccacaac ccattcaaca cattcagaag cctatccaac cgcaacaagt tcgtataccg 24
60

ccatcaacag ctcccgttca gaaaccagtt caagtctcag ctccctaocca tagtaatgtg 25
20

gcaccacaaa cttcatctca agcgtctgca gatgcacgca atccgctacc tccaaaaaca 25
80

agcccaccag ttagcaacac gcctatcaca gttgctcctg ttcacgcggc accaactact 26
40

tcggcaccat caacttcggt ggtaacgaga aggccaactt caaccacagc tcaaattgtcg 27
00

gacgaggaga gacggtcaag aattgccatg gacatcagct ctgcacttcc agctcccagt 27
60

gctttgctct atggatctaa ctccacatca tcaattccgt cagcggcagt gtctacagcg 28
20

tcttctgtgc catcaactgc aagagacaat ccagtggaaa caagaccatc tcaacctcat 28
80

gttaccatgc cacccaaaaa atcttctgag ccgattctct cgtctgaggt gctccaacca 29
40

actcgtctgc catctgccac aacttcgcag gcaaaaccag tgactcaacc aatccgtcac 30
00

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ccatcacctc cggtagccac tgttataccg actgcagtgg ttgacaaaaa gccagtttca 30
60
caaaatcaag gaagcaacgt tcctttgttt aacattacca actccagcaa cgggtaccct 31
20
cagttaaatg gatatccaaa ctatggaaac ggttttcagg cgtatgggta tggaatgaac 31
80
tatcatcaag gatatcctgg atatcaagga tacaattcat atggcaacgg aatggggcag 32
40
cttgcaactga cccacaacgc cgtcacttct ttgccaccgt tggttccatc agagaacaga 33
00
ttctccggaa cagcccaacc acttggcgag tctgacatta tggagttttt gggaacacag 33
60
caacgtcaag cgggttcttc atcgcgagca gttccacctg catctgcac cagctcagca 34
20
gctttctggaa tcacggattt gagtatggca gataagatgg aggtgttgta tagagaagct 34
80
gattttacgc ataaaggaaa ttgtgatacc atggtttctc agtgcaacgg aaacaccgaa 35
40
caggcggtga agcttctcaa acaacaacac ttggtggata tggaacttgc aatgtcaacg 36
00
gagaccgccc gacaagcact cgaggccaga cagtatgac tccctgcagc cgccaacatg 36
60
ttgctcggct ga 36
72

<210> 12
<211> 1335
<212> DNA
<213> Caenorhabditis elegans

<400> 12
atgtcaatta attctctttc gaacgaaacg cccactccaa caatcgagaa agaagcctac
60

ttccatggat tgatccaacg agaagatgtc ttccagctcc ttgacaataa tggcgactac 1

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
20

gtggtcagac tgtcggatcc aaagcccggc gagcctcgct cctacattct gagcgtcatg	1
80	
ttcaacaata agctcgatga gaacagttcg gtgaagcact ttgttatcaa ttctgtagag	2
40	
aacaaatatt ttgtgaacaa caatatgtcg ttcaacacga ttcaacaaat gctcagccac	3
00	
tatcagaaga gtcgcacgga gattctcgaa gcgtgcaaga ttttgcattcc tgtgcgcaga	3
60	
caattctggg agttagatca tggcaatatc gtgattgaga agaaactagg cgaagggtgct	4
20	
tttgggtgaag tttcctccgg agttatgaag ttcaagagag gtggaaggct ggtgaagggt	4
80	
gctgtgaagc aggtaaaaac cgatggtatc gggaaagatc aaatcaagga tttcctgatg	5
40	
gaagctcgta ccatgcgaaa cctcgggtcat ccaaacatcg taagattcct cggaatcgcc	6
00	
gtgctgcagg agccgctggt cctgggtgatg gagctcgcga cgggcggcgc tttggatagc	6
60	
tacttgaagc ataatgagtt gctgccgatt gacaagagac acgagatgct tcttcaagca	7
20	
gcatggggtc tcgagtacat ccatggaaaa cccatgctgc atagggacat cgccgcgcga	7
80	
aattgccttt atggagatgg gaagggttaa atttcggatt toggcctaac ccgtagagga	8
40	
accatctacc aattgcatcc ggagacgaag tcaccaattc gatggctggc agttgaaact	9
00	
atcaggacta tggtttgctc tcagaagact gacgtctggg cttaacgggat tctctgctgg	9
60	
gagatcttca acaacggagc cgagccgtat ccgggactga ctgccaatga ggttgctaag	10
20	
caggtgactg atggataccg tatgccacca caccagttgg ctgcgccaga ggttcaagcg	10

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
80

ttgatgacga gatgctgctg ggagaacccc aacgatcgtc caacaatgtc ggatgtcgtc 11
40

cagatcttgc aacgcgtcac tggtaagga cgtcccaact ttgcagcgat tgccaagaaa 12
00

gaggctgaag agcttctcat catgaattct cgtagtgtcaa ggagaacttc acgacgtaag 12
60

ggcagtaata agaagtcggc aattccaaac ggagttttta cacctgtcaa tagagctcaa 13
20

gaaattaagc attga 13
35

<210> 13

<211> 1689

<212> DNA

<213> Caenorhabditis elegans

<400> 13

atgttcatca gcaaagagga aatgaatcgt acttttggtg tcaaagctga gctgaattac
60

attgaaatgg ggaatgttag ctctgtactct acaaagtctc actacagagt tatggcaaac 1
20

atcgactacc tctcgttcac atggaatgct gttggaattg tacactatga agtttacgtc 1
80

gaatctgatg actcttctgt gcttcctatt gttcgaattc cattgaaagg aacggtgcca 2
40

gaatctttgc aggacttcac cgttgaatac agatgtgccg gacaccgatc cggacaattt 3
00

gctgtcagtc tatatttcac attcaaatat ggtaataagg agccgttgaa agtgaaattg 3
60

cgacaggaga agatctgctc ttcaaggagc ggacgtcgag gtctgaacgg aggctacgag 4
20

ggtcatgaag tcgacgacac tgactcaata gacaaggcat tttttgttat catttgcatt 4
80

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
gctgcggcat tcctacttat tgtggcagca acgttgatct gttatttcaa gcgctctaaa 5
40

aaagaagaca tgattccgac tgcacttcca acgtcttttc ggaattcttt gaaatctaca 6
00

aaaagcgcgc agccttttct tctgagcaca ccgcgagatg gacctccgac tctttccgct 6
60

atttcaagcg ctcccttgttc ttctgtctct gcgtcgggaa attcgataat cccgagcaag 7
20

ccaagaaaca ttgacgtgag acgtgcattg ttacaactct atcaagatcg agatgctttt 7
80

caatctctac ctctagatat ggaggggaaca ttggagaag tgagatatgc aatttggcgt 8
40

caagtagatg acgtactgaa cggagatggt gacgacgaag aagacacatt ctgtaaccag 9
00

gaagctgttt acacaaaaac gttgaaaaat aatgcctcac caattcagct ggatcggttt 9
60

ttgtccgacg cccttctatt ttacaacatc acacctcacc aaaacttgtc tcaagtggca 10
20

tgtgtggcctt ccttcggaag attcgaccgc ccggaaactg tcacagattt tccacttggt 10
80

tgttacagac accaaggcctt tggaaacctg aagaagtcc tcaccatctg ccgacatggt 11
40

gataaaaacta aaggagctca aactctccga actcatcaac tcgtctctct gccacacaa 12
00

gtatcttctg cagtagctca tatacacaaa tatagaatag tgcataacga cattgccgct 12
60

agaaaactgct tgatcgaga agtgaatggg cgactccaag tgcaattatg cgactcggcg 13
20

ctgtcccgcg atctgttccc agctgattat cactgcttgg gtgacaatga gaacagacca 13
80

ttgaaatgga tgtctccaga agctattgca aatgagctgt actcatcggc cgctgatgtt 14
40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 tggctactgg gagttctact gtgggagctc atgtcgctag gaggatctcc acacgctgaa 15
 00

atagaccctg aggaagtgtg cacaatgatt ctcaaaggaa agcgtctgca acagccgaac 15
 60

aattgtccgg atcaattata cgaagtcatt ctgtgctgtt ggagggtact cagcgaagat 16
 20

cgtcctagca gtgagcaggt agttcatgga cttcgagact ttaacattca actcagtcaa 16
 80

tacatctaa 16
 89

<210> 14

<211> 3603

<212> DNA

<213> Drosophila melanogaster

<400> 14

atgaacaccg cgggagccac cagtcaaccg ccgcccacta aaaatgagat taactccgag
 60

gagtatctca tccacgtgca tatgccgaac aagagcttca aggctgttcg gtttaatgtc 1
 20

aaggagaccg ttttccatgt gatccggcgc actgtcgagg atctgggcac ggatggacgg 1
 80

acgcccagca ttcagcgata tgctgcccgc atgcttaaca tgatcaccaa ggaggtgatt 2
 40

tggtctggcta gaagcacttc aatgcagaag gttctctcgc acatcctgac gcccggtgc 3
 00

tccaacgttg actgtcccaa caaccagtcg gagttggatg aggttctatt ggagcacgga 3
 60

agaaggatca ccgataatag ggtgtggcga gtggagctca gagtgcgcta cgtgccaaat 4
 20

aatattcaag agctcttcga ggaggacaag gccacatgct tctattatct caatcaggtg 4
 80

aaagaggact ttatccaagc caatgtcaca gccatcgaca ctgaagtggc ggtgcaactg 5
 40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

tgctgtctgg gcattcgtca ttatttcaag aacatcacccg tgaaagcacc tgacaaaaag 6
00

cagcacattg actacattga aaaggaaatc ggatttaaaa gttttcttcc acaatctgtg 6
60

atagccacat caaagccaaa gaatcttaag aaactgatcc aagtcggtta caaaaaggtc 7
20

tacaattaca acgacattga gtacttgacg cggttctttg atcttctgaa gaatatttat 7
80

ttaacgaact tcgagcagtt ctcggttaacc ctgagctcgg cgtggaatat ttctggaatt 8
40

ctacacgtcg gccctcacat tggaatctcg taccagactc atcctcaggc cagcttgaag 9
00

aacgtggctc agttttaaaga tgtggtctct attaaaacgt gcactttacc aaaggaaaaa 9
60

ctgtccaagt ctggggagaa taccacagaa ccagagcttc agaattttta ttgcaactgc 10
20

cagaagatta aaacccaaat aaaaatatcc gcttccaaca atgtggaaga tttggttata 10
80

acgtgcaatg gtattaatac cgotgagagt attgctgacc taattgacgg ttactgccgg 11
40

ctgttatcaa aagacctaga gttcacgatt tggcatcgag agacaaacgc gtcgaacgaa 12
00

gatagcgcaa aagcattgcc caatgatgog acgctggggg ccaataaata aacttcaagt 12
60

cagggaaaac cgatgctgac cgatgattat gccgagattg gtttattgga gggcgagggc 13
20

gactactcta cgcccaccgt tcgaaattat gagttggaca gagccctcat aacgccgagc 13
80

gccaaaattg gtgtgggaca gtttggtgat gtgtatgtag gcacgtatac gcttccgaaa 14
40

ctgggcaagg gcaagaactt agcaggaaat ggaaaaaata gtaatagtga ccaaagaaat 15
00

INT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gccgattcaa ggccagatgt tatacaagtg gcgataaaga catgtaaagc taacgacgat 15
60

cctgaaaaaa ccgaaaattt tcttgccgaa gcttatatta tgcaaaaatt cgatcatccc 16
20

catattatac gcttaatcgg catttgacgc gtaatgccca ttgggatagt tatggaattg 16
80

gccaaactgg gtgaattgcg tgcgtactta aagacaaaca gcgaaagatt aagccacggt 17
40

actttactga agtattgcta tcagctatcg actgctctta gttatttggga atccaaaaag 18
00

tttggtcacc gagatatagc ggcgcgtaat gtactagtca gtcaccaac gtgtgttaag 18
60

ttggctgatt ttggattatc acgttgggtt tccgatcagt cgtattatca ctcaacaccc 19
20

acagttgccc taccatttaa atggatgtcc cccgagtcaa taaactttag aagatttacc 19
80

actgctagtg atgtttggat gtttgggtgc tgcatttggg aaatactcat gctcgggtgta 20
40

aagcctttcc aaggcgtcaa gaacagcgat gttatattga agctcgaaaa cggagagcgt 21
00

ctgccattgc ctcccaactg cccacctagg ttatattcgt taatgtcca atgctgggag 21
60

tacgagccac ttaaacgacc gaatttcaag cggatcaagg aaactctgca tgaaattctg 22
20

attgaagaca gcattaattc atcggagaca ctgaagcggg agcaacgaaa agtggcttcc 22
80

atgtcctgga ttggcagtga tgacatcgac attccgccat cgaaaccttc aagggatgatg 23
40

cacgatcctg acatcaactg cttaatgcct gaaacaacgg ggctacctca gacctatatt 24
00

attgcacaaa atcccgcggt gctggccaaa ctgatgatgg agaaccacaaa acgaggcata 24
60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

aatccagcgg cgtacaccac accagcttcg ggcattcaca atgttttggg cgaaaaacta 25
20

cgacaacagc aaaaggatag caacagcgac agcgaatggg taattcaaga agaattgcta 25
80

cggcagagat cctgctcaat acctcaagga tcgctcaatg atcatcaggc tcaaattgtt 26
40

aagcttgact tcatgtcagc tggtccttcc agtttgccgg actgctcgaa ctccagttct 27
00

cgacctatga caccaaagtc caatctttct tcactgaagt cgaaccactc atcggcggat 27
60

catttgcca gcttgacatc tgcagaagaa cagatgggtt caaatgcacg aaacctgggc 28
20

agtgcagttc caagtcgacc acctaacgc gcagatgacg aagtttattg cgccaccaca 28
80

ctggtgggtca aatcaataat ggcgctgtca caaggtgtgg agaaagcgaa taccgagggg 29
40

tacttggaat tgggtaagaa cgtgggcgtc aagttgagaa acttgctaac atcggtggac 30
00

aaaatatcta taatatttcc agcacaggcc ctcaaggaag tgcaaattggc acatcaggta 30
60

ctttcaaaag acatgcacga attggtctca gcgatgcgat tggctcaaca atatagtgac 31
20

acaacgctgg attgtgaata tcgcaagagt atgctgtctg ctgccacgt tttggctatg 31
80

gacgcaaaa acctgtttga tgttgctgat tcgatacgtc aacgttatca gcatttatc 32
40

ccgccatccg ccacaaaaga aacaagttgt tcgtcaagtt tcgagtcgac ttctggatct 33
00

attgtcgcag agccagttaa tgaccttggg ggttatatca agactagcac ttctggagat 33
60

ttgcttcaaa acacaggaat atatgataat gatttgcatc atagcttcaa ctgcgaattg 34
20

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

cagttgcaaa acccaaaagc cagcatcgac ttaagcggcg gtggtagtct acagcgaggg 34
80

atgagccttg gcttggacac aaccaggtcg acaaacgaac cgttgccaat tgttgaggag 35
40

accctgggca gcccggtga acatatgtac tgcaatacgt ccgccttgca cggccacgcg 36
00

taa 36
03

<210> 15

<211> 2772

<212> DNA

<213> Drosophila melanogaster

<400> 15

atgcttattt tctacgcgaa gtacgcattt atcttctggt ttttcgtggg aagcaatcaa
60

ggtgaaatgt tgctaattga caaaatctct cagcataaga cgcttctcaa cgtcaccgct 1
20

tgcaccaga attgtctgga aaagggccag atggatttcc gaagctgttt aaaggactgc 1
80

aggattaatg gaacatttcc cggggctctg cgcaagggtgc aggaaaacta ccagatgaac 2
40

atgatctgcc gcacggagtc ggaaatcgtt ttccaaatag attgggtgca gcacagcagg 3
00

ggaaccgagc cggctccaaa tgccacctac ataatccggg tggatgctgt caaggacgac 3
60

aacaaagaaa ctgcgcttta cctgtctgat gacaacttcc tcactctgcc gggattggag 4
20

tccaactcta cccacaacat caccgccctg gcgatgcacg gagatggcag ctactccttg 4
80

atagcaaagg accagacctt cgccaccctc atccgaggct atcagcccag caaaatggga 5
40

gcggtgaatc tgctgcggtt tgtcccccaa ccagacgacc tgcatacat tgctgccgaa 6

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
00

atcgagtga agccatcggc ggagagcaac tgctatttcg acatggtgtc gtattcaacc 6
60

aacagcgtga atatggacga gccactggag gtgcagttcc gggatcgcaa aaagctgtac 7
20

aggcacacgg tggacaactt ggagtttgac aaacagtatc acgttggcgt aagaacggtg 7
80

aacataatga atcgactgga gagcgatctg cagtggctgc caatcgctgt tccaagctgc 8
40

ttggatttgt atccctataa ctacacactc tgcccacccc ataagccaga gaatcttact 9
00

gtgaccacga agcagtatct gccaaatatt ttggccctga acatcacctg ggcgcgtccc 9
60

agatacctgc cggataacta tacacttcac atctttgatc tattcaaagg aggtacggag 10
20

ctaaactata cacttgacca aaacaggagc cacttctatg tacccaagat cacggtactg 10
80

ggttcccatt tcgaagtaca tttggtggcc cagtcggcag gcggaaaaaa cgtatccggt 11
40

ttgacgttgg acaaggttca tcgaggtgtg ttgctgagcg agggcaacat ggtcaagttg 12
00

gtactcttta ttatcgtgcc catatgctgc attttgatgc tgtgctccct gacgttctgc 12
60

agacgaaatc gttcggaggt tcaggcgctg caaatggacg ctaaggacgc gaaggccagt 13
20

gaatttcac tctccctgat ggacagcagt ggcctgctgg tcaccctctc ggccaacgag 13
80

agtctggaag taatggacga gctggaggtg gagccacact cgggtgctcct tcaggatgtc 14
40

ctcggcgaag gagccttttg cttggtgcga cgtggagttt acaagaaacg ccaagtggcc 15
00

gtcaagttgc tgaaagatga accaaacgac gaggacgtat atgcgttcaa gtgcgaaatt 15

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
60

cagatgctca aggccgtggg caagcatcca aatattgtgg gtatcgtggg atactccact 20	16
cgttttagca accagatgat gttgctaatt gaatactgca gccttgaag cctgcagaac 80	16
tttttacgtg aggagtggaa gttcaggcag gagcaaaatg caattggact taagaagaac 40	17
cttgaacaga acgtggacaa cgcacggttt aaccgactcc ctagaaattc catccatgat 00	18
cgcatagagg atatcaacaa ctcgatgctg tccactgtgg aagaggagag tgaatcggat 60	18
cagacacact caagtcgatg tgagacctac accctcactc gaataaccaa tgcagccgac 20	19
aacaagggct atggcctgga ggacattgaa aacatcgggt ggagttacat tcccaaaacc 80	19
gctgaagctc caaaggatcg gccaaaacgg aagctgaagc cgcagcccaa gaaagactcg 40	20
aagcaggatt tcaaatcgga caacaagaag cgaatctttg agaacaagga atactttgat 00	21
tgccctgact catcggatac caagccccga ataccactga aatatgcaga ttgctagac 60	21
atcgcccaac aggtggcggt gggaatggaa tttctggccc aaaacaaagt agtgcatagg 20	22
gatctggctg cccggaatgt tctaattctc gtagatcgca gcatcaagat agcagatttt 80	22
gggctgagtc gagatgtgta tcatgagaac gtgtaccgaa agtccggagg aagtggcaag 40	23
ctgcccatac agtggctcgc gctggagtcc ctacccacc aggtgtacac cagtcagagc 00	24
gatgtttggt cctttggtgt gctgctctat gagatcacca ctctcgggtg aatgccatat 60	24
ccgtcgggtgt ctcccagtga tctcttgag ctactgcgac aaggtcatcg gatgaagcga 25	25

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
20

ccggagggat gtacgcaaga aatgttttcc ctgatggaaa gctgctggag ctccgtgcca 25
80

tcacacaggc caacattttc cgcccttaaa cacagacttg gtggcatgat tttggccact 26
40

aacgatgttc cagaaaggct gaaacaactg caagctgcaa ccgagtcaaa attaaagtca 27
00

tgtgacggtc taaacagtaa agtggagcaa gtgccatgcg aggaagagct atacctagaa 27
60

cctttgaatt aa 27
72

<210> 16

<211> 5229

<212> DNA

<213> Drosophila melanogaster

<400> 16

atgttcaata tgccacgggg agtgacaaaa agtaaattcca agcgtgggaa aattaagatg
60

gaaaacgata tggcagcagc agcaacaaca acagcctgca cgcttggaca catttgtgtt 1
20

ttgtgccggc aagaaatgtt gctggatata tgttgctgcc ggcaagcagt agaagcagtt 1
80

gacagccccg caagcagtga agaagcgtat agcagtagca acagcagcag ctgtcaagca 2
40

agcagtgaaa tcagtgcgga ggaggtctgg tttctcagtc atgatgatat cgtactgtgc 3
00

cgcagaccaa aatttgacga agtggagacg acgggtaaaa agagggacgt taaatgcagc 3
60

gggcatcagt gcagcaatga atgcgacgat ggcagcacga aaaacaatcg acaacagcgc 4
20

gaaaacttca atatcttttag caactgtcac aatatcttgc gaacattgca atcgtgtgtg 4
80

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
ctgctcatgt tcaattgcgg catittcaac aagcgacgca ggcggcagca tcagcagcag 5
40

catcatcatc attatcagca tcatcatcag cagcatcatc agcagcatca tcagcggcag 6
00

caagccaatg ttagttacac aaaattccta ttgctgtac aaacactggc agcagcaacc 6
60

acaagactga gttaaagccc taaaaactac aaacaacaac aacaactaca gcataaccaa 7
20

cagctgccac gtgccacacc gcaacaaaag caacaagaga aagataggca taagtgtttt 7
80

cactacaagc acaattactc ttactcgctt ggcattagcc ttctactctt tctctactg 8
40

gccaacacat tggccatcca agcgggtcgtg ttgccagcac atcagcagca cctgctgcac 9
00

aatgatatag ccgatggact ggataaaaca gcgctttcgg tgtcggggac gcaatcgca 9
60

tggacaagga gcgaatcaaa cccaacaatg cgactgtcac aaaatgtaaa accttgcaaa 10
20

tccatggaca tcaggaacat ggtgtgcac ttcaatcagc tggagaactg cacggtcatc 10
80

gagggttcc tgtgatcga ttgataaac gacgccagcc ctctgaacag aagctttcca 11
40

aaactgaccg aggtcacaga ttatatcata atctaccgtg tgactggatt gcactcgctg 12
00

tcaaagatct ttcccaatct gagcgtcatt aggggaaaca agctgttcga cggatatgcc 12
60

ttggtcgtct actcgaattt cgacctcatg gatttgggac ttcacaagct acgatccata 13
20

accagaggcg gtgtgcggat tgagaagaat cataagctgt gctatgatag gaccatcgat 13
80

tggctggaat ttctggcggg aaacgaaacc caactggtgg tgctgacaga gaacggcaag 14
40

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 gagaaggagt gcaggctttc caagtgcccg ggggagatca gaattgagga ggggcacgat 15
 00

accacgggcta ttgagggaga gcttaatgcc agttgtcagc tgcacaataa taggcgcctg 15
 60

tgctggaaca gcaaactctg ccagacgaaa tgccctgaaa agtgcagaaa taactgcatc 16
 20

gatgagcaca cctgctgcag ccaggattgt ttgggtggat gcgtgatcga taagaatggg 16
 80

aatgagagct gcatctcctg tcgaaatgtg tctttcaaca acatctgtat ggactcctgt 17
 40

ccgaaaggct attatcagtt cgacagccgc tgcgtaacgg cgaacgagtg catcacactg 18
 00

acaaagtttg aaacgaacag tgtgtattcc ggtattccat acaacggaca atgtatcacc 18
 60

cactgtccaa cgggggtacca gaagtcagag aacaagcgca tgtgcgaacc ttgtccgggc 19
 20

ggcaagtgtg acaaggagtg ctctccgggt cttatcgaca gtttggagcg tgctcgggag 19
 80

ttccacggct gcaccattat aaccggaacc gagcccctta ccatcagcat taaacgtgaa 20
 40

agcggcgctc acgtcatgga tgaattaaaa tatggcctgg ctgccgtcca taaaattcag 21
 00

tcgtccctaa tggttcattt gacctacgga ttgaagtcct tgaaattctt tcaatcccta 21
 60

actgaaatta gcggcgatcc gccgatggac gcggataaat atgctttgta tgtgcttgat 22
 20

aatcgcgatc tagatgagct ctggggaccc aaccaaacgg tgttcattag gaagggcggc 22
 80

gtcttctttc atttcaaccc aaaactatgt gtgtccacca ttaaccagtt gctgcccattg 23
 40

ctggcctcca agccaaagtt ttttgaaaag tcagatgtgg gcgcagactc gaatggaaac 24
 00

'ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 cgcgatcat gtggaacagc cgttctcaat gtcacattac aatcagtggg agcaaactcc 24
 60
 gctatgctga acgtcacgac aaaagttgaa ataggagagc cccaaaagcc gagcaatgct 25
 20
 acaattgttt ttaaggatcc gcgcgccttc atcggtttcg tgttttatca tatgatcgat 25
 80
 ccgtacggga actcaactaa aagcagtgc gatccatgcg atgatcgctg gaaggtagc 26
 40
 tctccgaaa agagcggggc catggtatta agcaatttga ttccgtacac taactactcc 27
 00
 tactacgttc ggaccatggc tatatcctcg gaattgacaa acgcggagag cgacgtgaag 27
 60
 aactttagga cgaatcccgg acgaccgtca aaggttacgg aggtggtagc aaccgccatt 28
 20
 tcagattcga aaattaacgt aacatggagc tacctagata agccttatgg cgtgctaacg 28
 80
 cgctatttta taaagccaa acttataaat cggcctactc gaaacaataa ccgggattac 29
 40
 tgtactgaac ctctcgtcaa ggccatggaa aatgacctgc cagccacaac gcctaccaag 30
 00
 aaaatatcag atccttttagc aggcgactgt aagtgcgtgg agggttcgaa gaagactagc 30
 60
 agtcaggaat acgatgatcg taaagttcaa gcgggcatgg agtttgagaa cgcgttgcaa 31
 20
 aactttatat ttgttccaaa cattcggaaa agcaagaatg gatcgtctga caaatcagac 31
 80
 ggagcggaag gtgcagctct cgattctaata gctattccaa atggaggagc tactaaccct 32
 40
 tcacgtagaa ggagagacgt tgcgctcgag ccagagctcg acgatgtaga gggcagtgt 33
 00
 cttctacgcc atgtgcgctc catcacagac gataccgatg catttttcga aaaggacgac 33
 60

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 gaaaatacct ataaagacga agaagacttg tcctccaaca aacaattcta tgagggtgtt 34
 20
 gccaaaggaat tgccaccaaaa tcaaacacat tttgtctttg aaaaactgcg ccacttcacc 34
 80
 cgctacgcta tcttcgtggt agcctgtaga gaagaaatcc ccagcgaaaa attaaggagac 35
 40
 accagtttta agaagtcgct ctgcagcgat tatgacaccg ttttccaaac taaaaagaga 36
 00
 aagaaatttg ccgacatagt catggaccta aaagtagatt tagaacacgc caacaacacc 36
 60
 gagtccccag tacgggttcg ctggacgcca ccagtagatc ccaacggaga aattgtcacc 37
 20
 tatgaagtgg cctacaagtt gcaaaaaccc gatcaagtgg aagaaaagaa gtgcattccg 37
 80
 gctgctgact tcaaccagac tgccggttat ttaataaagc tcaacgaggg cctttacagc 38
 40
 ttcaggggtgc gagccaattc aatagcggga tacggcgatt tcacggaagt cgaacatata 39
 00
 aaagttgagc ctccgccgag ctatgctaag gtctttttct ggctactggg aatcggccta 39
 60
 gcgttcctga tcgtttccct gttcggctat gtctgttacc tgcacaagag gaagggtccc 40
 20
 tctaatagacc ttcatatgaa cacagaggtg aatccgttct atgcgagcat gcaatacatc 40
 80
 ccagacgatt gggaggtgct gcgagagaac atcattcagt tggctccact aggccaggga 41
 40
 tcctttggca tgggtgatga gggatcctg aagtcctttc cacccaatgg cgtggatcgc 42
 00
 gagtgtgcca ttaagactgt caacgaaaat gctacggatc gcgagcgaac caatttcctg 42
 60
 agcgaggcga gcgtcatgaa ggagttcgat acgtatcatg tcgtaagatt gctcgggtgtt 43
 20

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

tgctccaggg gtcagccggc tctgggtggc atggagctaa tgaagaaggg tgatcttaag 43
80

tcctatttgc gtgcccacgc tcccagaggag cgggatgagg ccatgatgac gtatcttaat 44
40

cgcatcggag tgactggtaa tgtgcagcct cctacttatg gaagaatcta ccagatggcc 45
00

attgagattg cggatggcat ggcatatttg gccgccaaga agttcgtcca tcgtgatctt 45
60

gcagctcgaa attgcatggc tgctgatgat ttgacgggta aaattgggtga ctttggaatg 46
20

accggtgaca tctatgagac ggattactat cggaagggca ctaaagggct gctgccagtt 46
80

cgctggatgc caccggagag cttgcgagat ggtgtctact ctagtgccag tgatgtattc 47
40

agctttggag tggttctctg ggaaatggcc acctagcgg ctcagccata ccagggactt 48
00

tccaacgagc aagtcctgcg ttacgtcatc gatggcggtg ttatggagag gccggaaaat 48
60

tgtcctgatt ttctgcataa actaatgcaa aggtgctggc atcataggtc ttcggcgaga 49
20

cccagttttc tggatatcat tgcgtatctc gaaccacaat gcccgaattc acaatttaag 49
80

gaagtatcct tctatcactc agaggcaggt ctgcagcatc gggaaaagga gcgcaaggaa 50
40

cgcaatcagc tagatgcatt cgcggcagtc cccttggatc aagatctgca ggatcgggaa 51
00

cagcaggagg atgctaccac acctttacga atgggagatt atcagcagaa ctctcgttg 51
60

gatcaaccgc ccgaaagccc catcgccatg gttcctgcca tccggattca ttgcgagcag 52
20

tactcctga 52
29

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

```

<210> 17
<211> 2058
<212> DNA
<213> Drosophila melanogaster

<400> 17
atgaacaaat actcggcatt tatagtctgc atttcgctcg tgcttttatt tacaaaaaag
60

gatgtgggga gccataatgt ggactcaaga atatatgggt tccagcaatc atcaggtatt 1
20

tgccatattt acaatggcac catttgtcgc gatgtcttga gcaatgccca tgttttcgta 1
80

tcccccaatc tcaccatgaa cgatttggag gagcgattaa aggcagctta tggagtaatc 2
40

aaggaatcca aggatatgaa cgcaaattgc cgcattgtacg ctttgcccag cttgtgtttc 3
00

agttcaatgc caatttgccg gactccagag cgcacgaatc tcttgtactt cgccaacgtg 3
60

gccacaaatg ccaagcaact gaagaacgtc agcattcgac ggaagagaac caagtccaag 4
20

gacattaaga acataagcat attcaagaag aagtccacca tctacgagga tgtgttcagc 4
80

acagacatat cgagtaaata cccaccaacc agagagtctg agaacctaaa acgcatttgc 5
40

cgcgaaagagt gcgaacttct ggagaacgag ctgtgccaga aggaatatgc cattgccaaag 6
00

cgacatcccg tcatcgggat ggtgggtgtg gaggattgcc aaaagttgcc gcagcacaag 6
60

gactgcctat ccttgggcat caccatcgag gtggataaga cggagaattg ttactgggag 7
20

gatggatcga catatagagg agtggccaac gtctccgcat ccggaaagcc atgtttgcga 7
80

tggtcatggc tgatgaagga aatctccgat ttccctgaac tcatcgggtca gaattattgc 8
40

```


ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

```

agaaatcctg gaagcgttga aaatagtoct tgggtgttttg tggactcctc acgtgaacgc      9
00

ataatcgaac tttgtgatat tccaaaatgt gcggacaaaa tatggattgc cattgtcgga      9
60

acgactgcag ccattattct aatattcata attatatattg cgataatact tttcaaaagg     10
20

agaacaatca tgcactatgg aatgaggaat attcataata tcaacacacc cagcgccgat     10
80

aaaaatatct acggaaattc gcagcttaat aacgcacaag atgctggcag gggaaatctg     11
40

ggaaatctat ccgatcacgt tgctttgaac tccaaactta tcgaaagaaa tactctgctg     12
00

aggataaacc attttacgct gcaggatgtt gagtttctgg aggagctggg cgaaggagct     12
60

tttggaaaag tctacaaggg acagctcctg cagccgaaca aaaccaccat aacagttgcc     13
20

atcaaggcgt tgaaggaaaa cgcctcgggtg aaaacgcagc aggactttaa gcgcgaaatc     13
80

gaactaatct cggatctaaa gcatcagaat atagtgtgca tattgggcgt agtgcctaat     14
40

aaggagccct actgcatgct gttcgagtac atggccaatg gtgatctgca cgaattccta     15
00

atctcaaact caccaccga aggcaagtcg ctgtcgcagt tggaaattcct gcaaatagct     15
60

ctacaaatca gcgaaggaat gcagtatctg tcggcccatc attacgtaca tcgcgacttg     16
20

gcagctcgga attgcctggg aaacgagggg ctggttggtga agatatccga ttttggacta     16
80

tccagagaca ttacagctc agattattat cgagttcagt caaagtcgct attgcctgta     17
40

aggtggatgc cctcggaatc gatattgtat ggaaagttta cgaccgagag cgatgtttgg     18
00

```

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

tccttttgag tcgttctttg ggaaatatac agctatggaa tgcagccata ctacggtttt 18
 60
 agcaatcagg aagtaatcaa tctcatccgt tcacggcaac tgctctccgc tccggaaaac 19
 20
 tgtccactg ctgtctactc gctaattgatc gagtgctggc atgagcagtc agtaaaacgt 19
 80
 ccaacattca cagatatttc gaaccgtctc aaaacttggc acgagggcca cttaaaggcc 20
 40
 agtaatccag aaatgtaa 20
 58

 <210> 18
 <211> 1554
 <212> DNA
 <213> *Drosophila melanogaster*

 <400> 18
 atgggtaact gcctcaccac acagaagggc gaacccgaca agcccgaga tcgaatcaag
 60
 ctggacgacc cgcccacat cggagtcgga gtgggcgtgc cacaatccc catgccctca 1
 20
 cacgccggac agccaccgga gcagatacgt ccggttcccc agatcccgga gagcgaaacg 1
 80
 gcaggtgcca acgccaagat ttttgctgcc ctctacgact acgacgccc caccgacgag 2
 40
 gatttgagct tccgcaaggg agagcacttg gagatactga atgacacgca gggtgactgg 3
 00
 tggctggcgc ggagcaagaa gacacgttcg gaaggctaca ttccatcaa ttatgtggcc 3
 60
 aagttgaaat caatcgaagc agaaccgtgg tacttccgca aaatcaaacg cattgaggct 4
 20
 gagaaaaaac ttctactgcc agagaacgag cacggtgcat ttttaattcg cgattccgaa 4
 80
 agccgtcaca acgactactc gctatcagtg cgcgatggcg atacggttaa gcattatcgc 5

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
40

atcagacaat tggacgaagg cggcttcttc atcgccaggc gcacgacatt cagaaccctt 00	6
caggagctgg tggaacacta ttcgaaggac tctgatggcc tatgcgtcaa cctctgcaag 60	6
ccgtgtgtcc agatcgagaa gcctgtaact gaggggcttt cgcaccgcac tcgcatcag 20	7
tgggagatcg acagaacgtc tttgaaattc gtgcgcaaac tgggctccgg acagtttggc 80	7
gatgtctggg agggattgtg gaacaacaca acacctgtgg caattaaaac tctgaaatct 40	8
ggtacaatgg accccaagga tttcttagcg gaagcccaga tcatgaagaa actgcgccac 00	9
accaagctta tacagttgta cgctgtctgc actgttgagg agcctatcta tattatcaca 60	9
gagttaatga agcacggttc actgttgga tctctccaag ccattgcagg caagggtcgt 20	10
agccttaaaa tgcaaaactct gattgatatg gcagcgcaaa tagctgctgg catggcttac 80	10
ttggagtccc agaattatat tcatagggat ttagcggcgc gcaatgtact ggtaggcgat 40	11
ggaaacatcg tcaaaatcgc cgactttggt ttagctaggc tcatcaagga ggacgaatac 00	12
gaggcgcggg taggcgccag atttcccata aaatggaccg ctccagaggc tgctaactac 60	12
agcaaattct caataaaatc ggatgtttgg agctttggca ttcttctcac agaactggtc 20	13
acctacggac gcataccata tccaggcatg accaacgctg aggtgctaac gcaagtggag 80	13
cacggctatc gaatgccgca acctcccaac tgcgagccgc gcctgtatga gattatgctg 40	14
gaatgttggc acaaggaccc catgcgcaga cccacgtttg agacgtaca atggaaactg	15

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
00

gaagacttct atacatctga tcagagcgac tacaaagagg cgcaggccta ctga 15
54

<210> 19

<211> 1779

<212> DNA

<213> Drosophila melanogaster

<400> 19

atgatcaagt gcgccctgaa cgaggtggga tgcgaggagc tgccctccgg ttgcgacgat
60

gacctcacc tggagcagaa cttcatcgag aatggctata acaacgaaca gcagagcaat 1
20

agcaatcaca gtgcctcaca gtccacgata ataacgagca cgatcaccac caccataacg 1
80

actacaacta ccacgacgcc gtccaaggaa aactcaagac tgaaattcaa agtgcccaag 2
40

atccagaaga aatcaaaggc catccgcaat acattccgct ccaagttgct caatttccag 3
00

ttgaagcgct ccaagccgtg caaacagtgc accaagagac gtcgcatcca tcccagcaaa 3
60

agtgtctttg attttgccaa agagttcgag gtggaacaac cggctgggtc ggcggcggat 4
20

gagcaattct gcaactgtcc gccagctggt caaaagcctg ttaagccatc cgtccaaata 4
80

tccggccaca aagatcacc gttcgagtcc agttctggag agctggacga gaactcggat 5
40

cgggacatcg acaacgacga ggaggaggag gatagcgcca gtgacgacgt gctcagcatg 6
00

aaggatcact gctattgctg gccagcctg gcggccagta tatcgctctc cacaaatcgt 6
60

ccgctttacg aggaggaatg gttccatggc gttctgccgc gcgaggaagt ggttcgattg 7
20

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ctgaataacg atggtgactt cctggtccgc gaaacgattc gaaacgagga gagccagatt 7
 80
 gtgctcagtg tctgttggaa tggccataag cacttcattg tccagaccac cggagagggg 8
 40
 aatttcgggt tcgagggacc accatttgcc agcatccagg agctgatcat gcatcagtat 9
 00
 cactcggaat tgccagtgac cgtgaaatcg ggagccatac tccgacgacc cgtttgccgg 9
 60
 gagcgctggg agctgagcaa cgatgatgtg gtacttctgg agaggattgg tcggggaaac 10
 20
 tttggggatg tctacaaggc caaactgaag tccaccaaac tggatgtggc tgtcaaaacc 10
 80
 tgtcgaatga ccctgcccga cgaacagaag cgtaaattcc tacaggaagg gcgcaccc 11
 40
 aagcaatacg atcatccaaa tatcgtaaaa ttgattggca tttgtgtgca gaagcagccc 12
 00
 atcatgattg tcatggaatt ggtgctcggg gggttcgcttt taacttatatt acgcaagaac 12
 60
 tccaatggcc tcaccactcg ccaacaaatg ggcatgtgca gagatgcggc ggcaggcatg 13
 20
 cgatatctgg agtccaaaaa ctgcattcat cgcgatctgg cggcgcgtaa ttgtctcggt 13
 80
 gacttggagc acagtgtgaa gatctccgat ttcggaatgt ctgcgagga agaggaatat 14
 40
 atagtltccg atggcatgaa acaaatacct gtgaagtgga cagctcccga ggcottgaat 15
 00
 ttcggcaagt acacttcgtt gtgcgatgtg tggtoctatg gcatactgat gtgggagatc 15
 60
 ttctccaagg gcgacacacc ctactccggc atgaccaact ccagagccag agagcgcac 16
 20
 gatacgggat atcgtatgcc aacgccgaag agcacgcccg aggagatgta ccgactgatg 16
 80

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
ctccagtgtc gggcagccga cgccgaatcc cgaccgcatt tcgatgagat ctacaatgtg 17
40

gtggatgcac tgattctgcg cctggacaac agccactaa 17
79

<210> 20

<211> 2685

<212> DNA

<213> Caenorhabditis elegans

<400> 20

atgcaccatc ccaaagaaac gcttcttatac gattcatcta atcctttotta ctcccacctc
60

accgagtacc gttttgataa cctgaaacgt gaagagtctc gatcgacctc actttttggc 1
20

gacaggagaa gagtgatgaa aatcctgagt ggattttccc tcattattat tgcgttttc 1
80

atatttgcta caagtcatga acaggcgctc tctaccactg gagacctcac ttcgagtact 2
40

cagagtacta cacatggagg tgttgtcttt acatatccaa ctacaagaaa atctcccggc 3
00

aaaggatgtg tcctgaattc gcagagatca acgcctaaaa acttgaaaca gtacactgga 3
60

aacatttcag acgcttggtt agccggaata aaatcaagta actgtaagac atggctaattg 4
20

acaaatgcgg tgattttgaa atactcagac gatgttgtca gcaattgccc ttcgattttg 4
80

gaatttgtga ataaaacatc gttatcatgt tcgggtaaaa gtcagattca atatatgtat 5
40

cctcagagtg attctgcgtc aagtgattgc aatcactctt atgacttcaa ctcaaattgct 6
00

ctgaacagag caatatataa cttcaactac agcaagacct taatctccac gtcatatgcc 6
60

aatactcctg gattcgctat gtatacatc ttgctgaaga ttatgaactg tgtcaacaaa 7
20

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

aacggaataa aacttgacgc cggaattctc aacattttta cggacatgac ctatatatgat 7
 80
 ttatgtgaaa gtgatgtttt catgagctcg tttccagata ctctgaacaa gcttattgag 8
 40
 gcggggtata ttgtcaaatt ttatttcctg aatcaaaatt tgcaagatac tcaaaaaaac 9
 00
 gttgaaaacy tactagctgg atgtaaatac atgaattcaa gatcgtactg cgaaattgta 9
 60
 gactggagct atcattcgga aaatcctaata gagtttgaaa tttgcatccc agattcacag 10
 20
 ccagtgggga agaaagaaga ctttaattgg caacttcttc taattattgg tataccttgt 10
 80
 ataagtttga caatttgctg cattgcattt ttcgtttgtt gcttgaaatg tgctaaactg 11
 40
 aaaatggcaa tgatgagaat gaatgtattc tcaaatagata ctacacaaaa tcctgatgaa 12
 00
 atggagctga aaaagagatg gatcgggatg agaaagaaat tcaataaaga tgttgagaat 12
 60
 ggaagttgta aagagttaaa caccacaaaa tgggtctcact tcgcatcggc gaacaattac 13
 20
 atggacatac aagcattggc aaatgctaata aaaaaagata tatgggaaat tgacacaaaa 13
 80
 aatctgctcg tccaggaaga ccatctcctt ggaaacgggtg catttgcaaa cgtctataag 14
 40
 ggaatcgtaa aaggaaaaat accactacta gttgtaaata atagtctcaa catgaccgta 15
 00
 gaatcagaaa acaatgggtca ctatgaagct gccatcaaga agttaccagc ccatgctgac 15
 60
 gagcagaacc atttggattt tttccatgaa attgatttta tgaagcgttt gggccatcat 16
 20
 ccacatgtca tcagcatgtt gggatgtgtg tcaaataccat atgagccatt gatcgtggtg 16
 80

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gagtattgcg cacgtggtga cctgttgaag tttttgagaa gacataaaga ttatgtgctg 17
40

atgaatcgtg tacatattga attatgtata agtatataca agttcaaatt aaaacttaga 18
00

ccgaacattg agattttcaaa aatcagtttc cagaacaaaa cagacgattg tccaattgaa 18
60

gcagacatgt gtctcagaat caaagatttg gtttctattg cttggcaagt tgccgatgga 19
20

atgtcatacc tggcatcaaa aaactttatt caccgtgatt tagctgcccg taacattctg 19
80

ctcacaaaaa gtttaactgc aaaggttagt gacttcggtc tatgtcggta tatggattca 20
40

gcactttata ccgcaaaggg gggccgtctc cccatcaaatt ggatgtctgt agaagcattg 21
00

aaactgtacg aattctccac aaaaactgat gtttggtcgt ttggagtgtt gttgttcgag 21
60

attttctcca tgggagatgt tccgtatcca acaatacaac aagtagatat gctggaacac 22
20

cttctcgctg gtggccgctt gtcacagcca ttgaaatgtc cgaatgagat atttaatatc 22
80

atgcagaaat gttgggccga aaagcctgaa gacagaccag agtttaatga aatgagagga 23
40

gaaatcacag tgatgttgaa cttggacgat gaaagttatg gatattcttag cgtcgagtca 24
00

cagggtggtc caaagtatac acaattaaca atgcaagatt caaaggaaac agctccatgc 24
60

tccactcctg gaggatcaca agatatggac gaagacgggg attatgatag tggctcagaa 25
20

ggccactcgc aaggaacttg tgctcagctc gaccaggttt tgactgagag atttggtgaa 25
80

gaacagaaga aggaaatcaa gcaaatcttt tgtgagatca cttcgaaatc aatgcgaggc 26
40

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

aaacgccgtc aatcgaattc tacagtcagc acgtatcaat cttga 26
85

<210> 21
<211> 2376
<212> DNA
<213> Caenorhabditis elegans

<400> 21
atgttttcagg agaatgcagt caccaattgg gaatgtcaaa tcgaaagatt cgtgatgagc
60
aaatctcggc gtcttcgagt ttcgacttgc aaagcactgg acctcaacat gctcggtaag 1
20
tggtttggga actactcatt tgaaattcgt actacagctc atcaagaatc tggaagtggc 1
80
gcctgggtgtc cgaagaatca aataaactct ctcagcaaag aatgggttgca gatttcgttt 2
40
tccgtggata cagtaataac ttctgtggag acccaggac gatttgacga cggacgtgga 3
00
atggagtatg cgaccgcatt caaaattcag tactggcgac cttcgctaaa cgcattgggca 3
60
tcttataaag acgattttga gctagagaca attcctgcta ataattgacac ggagcacgca 4
20
atccggcgac atcttgaccg ggcaatcata gcaagaagaa tcagaattgt tccagtttca 4
80
aattccacca gaactgtttg catgagagtt gaagttttcg gatgccatt tgatgatagt 5
40
ctcgtgtttt acaatgtcga tcaaggcgat ttgcaatctg gcatctctta tcacgacttt 6
00
tcctacgatg gtaatctcgc caactctcca cacttaaccg gcggtattgg gaagttatac 6
60
gacggcgaag tgggaaaaaa caatgtatgt gttaatcacc acaaattgggt tggatggaga 7
20
cgtaaaagaa atggcaatgt gaagttggca tttgagtttt ccgaattgag aaatatatca 7

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
80

```

gggattttga ttcatacgtc gaacgagttc aaaaagagcg caaaggcatt ttcctcggct      8
40
actgtgctat tttcgataaa tggaaaagac ttctcagaca ccatcgtaca cttcaataat      9
00
ccggaagata ccgaatcaga ggtacctoga tggataagga ttccagtga caatcggatt      9
60
gccaaagttag caaagattcg tcttaacttt ggaactgact ccgactggct gttcattttct    10
20
gaagtgaatt ttgaatcaaa tcacacaaat attgagcttc tcaatgatga cgtgggttatt    10
80
cccgattcgg tttcatatth ctccgtaacc gagcacgatg acggaactag catgttttgc      11
40
ttcattatct tcttcttcat gttcctcatc gtggcagtca ttattctgac agttctctac    12
00
cgtaaacgcg agtatcgtgt gaaagcatcg tctccatctc caaatgcgaa acgggaaatt      12
60
ctgttgacaa ttgacggaaa caccatcaag catcacgttt ctccgtcaac ctatcaaatg      13
20
gctcgcgata atcttcagaa tgcgttgatt gagaaaaatgc ccatgtcacc gattataagc      13
80
gattacgctg aaccggacat tagtgtttgc tccgatgtca ccgccaacac tccattgctc      14
40
tatggaattg atggtccata tgatacacag aagagaagca accctttgtc atctatggta      15
00
aaatactccg attatggaga ggtttattgc acaacacttc cggaatttgc tcgagacaag      15
60
ttgatttgcg tgagcagaat tgggcaagga gagtttgggtg aagtcgattt gtgtcagctt      16
20
gaaaaccgaa aagttgcggt caaaaaactt catggaatca gtcaagccga cgagttttct      16
80
tttcatagag aaattcgagt attaggaagt ctcaaacatc cgaacgtagt tgaagtcgtc      17

```

ENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
40

ggagtatgca ctatacaaaa accaatactc tgtatcatgg aatatatgga aaatggcgac 18
00

ttgaaatcct acattttgaa aaaccctact atacaaacct cccaatgcat ctcaatttgc 18
60

acacagcttg ccgcaggact tgcctatttg gaatcatgta attttgtgca tagagatatt 19
20

gctgctcgaa attgcottgt tgacggagaa ggcaatgtaa aaattgccga tttcggaatg 19
80

gcccgatctc tttattctca agaataattac aaagttgagg gaaagtttgt gctcccgatt 20
40

cgctggatgg catgggaagc tttgctactc ggcaaatttt ccaactgccag tgatgtttgg 21
00

ggattcggag ttaccatgtg ggagatcttc tcgctgtgct ccgaaaaacc atactccgat 21
60

atgacagatg atgatgtggt ggagaatctt cagagcatga gctctactgg atcattaaag 22
20

caagttcttt cccgaccaag gatgtgtcca tcaaagttgt acaacgagca aattcttccg 22
80

tgctggaact atgagagcag tcgccgaccc agtttcgaga acgtccatct tcacctccag 23
40

tcattggtgc acacttctcc tcatattcat ttttaa 23
76

<210> 22

<211> 3390

<212> DNA

<213> Mus musculus

<400> 22

atgggaatgg cctgccttac aatgacagaa atggaggcaa cctccacatc tctgtacat
60

cagaatggtg atattcctgg aagtgcta tctgtgaagc agatagagcc agtccttcaa 1
20

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
 gtgtatctgt accattctct tgggcaagct gaaggagagt atctgaagtt tccaagtgga 1
 80

gagtatgttg cagaagaaat ttgtgtggct gcttctaaag cttgtggtat tacgcctgtg 2
 40

tatcataata tgtttgcgtt aatgagtga accgaaagga tctggtaccc acccaatcat 3
 00

gtcttcaca tagacgagtc aaccaggcat gacatactct acaggataag gttctacttc 3
 60

cctcattggt actgtagtgg cagcagcaga acctacagat acggagtgtc ccgtggggct 4
 20

gaagctcctc tgcttgatga ctttgtcatg tcttaccttt ttgttcagtg gcggcatgat 4
 80

tttgtccacg gatggataaa agtacctgtg actcatgaaa ctcaggaaga gtgtcttggg 5
 40

atggcgggtg tagacatgat gagaatagct aaggagaaaag accagactcc actggctgtc 6
 00

tataactctg tcagctacaa gacattctta ccaaagtgcg ttcgagcgaa gatccaagac 6
 60

tatcacattt taaccggaa gcgaatcagg tacagatttc gcagattcat tcagcaattc 7
 20

agtcaatgta aagccactgc caggaacctt aaacttaagt atcttataaa cctggaaacc 7
 80

ctgcagtctg ccttctacac agaacagttt gaagtaaaaag aatctgcaag aggtccttca 8
 40

ggtgaggaga tttttgcaac cattataata actggaaacg gtggaattca gtggtcaaga 9
 00

gggaaacata aggaaagtga gacactgaca gaacaggacg tacagttata ttgtgatttc 9
 60

cctgatatta ttgatgtcag tattaagcaa gcaaaccagg aatgctcaaa tgaaagtaga 10
 20

attgtaactg tccataaaca agatggtaaa gttttggaga tagaacttag ctcatataaa 10
 80

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gaagccttgt cattcgtgtc attaattgac gggattaca gactaactgc ggatgcgcac 11
40

cattacctct gcaaagaggt ggctcccca gctgtgctcg agaacataca cagcaactgc 12
00

caggcccaa tatcaatgga ttttgccatt agcaaactaa agaaggcggg taaccagact 12
60

ggactatatg tgctacgatg cagccctaag gacttcaaca aatactttct gacctttgct 13
20

gttgagcgag aaaatgtcat tgaatataaa cactgtttga ttacgaagaa tgagaatgga 13
80

gaatacaacc tcagcgggac taataggaac ttcagtaacc ttaaggacct tttgaattgc 14
40

taccagatgg aaactgtgcg ctacagacagt atcatcttcc agtttaccaa atgctgcccc 15
00

ccaaagccaa aagataaatc aaaccttctc gtcttcagaa caaatggat tttctgatgtt 15
60

cagatctcac caacattaca gaggcataat aatgtgaatc aaatgggtgtt tcacaaaatc 16
20

aggaatgaag atttaatat taatgaaagt cttggccaag gtacttttac aaaaattttt 16
80

aaaggtgtaa gaagagaagt tggagattat ggtcaactgc acaaacgga agttcttttg 17
40

aaagtcctag ataaagcaca taggaactat tcagagtctt tcttcgaagc agcaagcatg 18
00

atgagtcagc tttctcacia gcatttggtt ttgaattatg gtgtctgtgt ctgtggagag 18
60

gagaacattc tggttcaaga atttgtaaaa tttggatcac tggatacata cctgaagaag 19
20

aacaaaaatt ccataaatat attatggaaa cttggagtgg ctaagcagtt ggcatgggcc 19
80

atgcattttc tagaagaaaa atcccttatt catgggaatg tgtgtgctaa aaatatcctg 20
40

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

cttatcagag aagaagacag gagaacgggg aaccacctt tcatcaaact tagtgatcct 21
00

ggcattagca ttacagttct accgaaggac attcttcagg agagaatacc atgggtacct 21
60

cctgaatgca ttgagaatcc taaaaatctc aatctggcaa cagacaagtg gagcttcggg 22
20

accactctgt gggagatctg cagtggagga gataagcccc tgagtgtctt ggattctcaa 22
80

agaaagctgc agttctatga agataagcat cagcttcctg cacccaagtg gacagagtta 23
40

gcaaacctta taaataattg catggactat gagccagatt tcaggcctgc tttcagagct 24
00

gtcatccgtg atcttaacag cctgtttact ccagattatg aactactaac agaaaatgac 24
60

atgctaccaa acatgagaat aggtgcccta gggttttctg gtgcttttga agacagggac 25
20

cctacacagt ttgaagagag acacttgaag tttctacagc agcttggcaa aggtaacttc 25
80

gggagtgtgg agatgtgccg ctatgacccg ctgcaggaca acactggcga ggtggtcgct 26
40

gtgaagaaac tccagcacag cactgaagag cacctccgag actttgagag ggagatcgag 27
00

atcctgaaat ccttgcagca tgacaacatc gtcaagtaca agggagtgtg ctacagtgcg 27
60

ggtcggcgca acctaagatt aattatggaa tatttaccat atggaagttt acgagactat 28
20

ctccaaaaac ataaagaacg gatagatcac aaaaaacttc ttcaatacac atctcagata 28
80

tgcaagggca tggaatatct tggtaaaaa aggtatatcc acagggacct ggcaacaagg 29
40

aacatattgg tggaaaatga gaacagggtt aaaataggag acttcggatt aaccaaagtc 30
00

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

ttgccgcagg acaaagaata ctacaaagta aaggagccag gggaaagccc catattctgg 30
60

tacgcacctc aatccttgac ggagagcaag ttttctgtgg cctcagatgt gtggagcttt 31
20

ggagtgggtc tatacgaact tttcacatac atcgagaaga gtaaaagtcc acccgtggaa 31
80

tttatgcgaa tgattggcaa tgataaaca gggcaaata ttgtgttcca tttgatagag 32
40

ctactgaaga gcaacggaag attgccaagg ccagaaggat gccagatga gatttatgtg 33
00

atcatgacag agtgctggaa caacaatgtg agccagcgtc cctccttcag ggacctttcg 33
60

ttcgggtgga tcaaatacggtg gacagtatag 33
90

<210> 23

<211> 3246

<212> DNA

<213> Mus musculus

<400> 23

atggcacctc caagtgagga gacacctctg atccctcagc gctcttgag cctctcatcc 60

tcagaggcag gagccctgca tgtgctcctt cctccccggg gacctgggcc tccccagcga 1
20

ttgtcattct cttttgggga ctacttggct gaggatttat gtgtgagagc tgccaaggcc 1
80

tgtggcatcc tgccctgttta tcattcgctt ttgctctgg ccaactgagga cttctcttgc 2
40

tggtttcccc caagccacat cttctgcata gaggacgtgg aactcaagt cttgggtctac 3
00

aggctacgct tttatttccc tgactgggtt gggctggaga catgtcaccg ctttgggctg 3
60

cgcaaagatt tgaccagtgc catccttgac ttacatgttt tagaacatct ctttgctcag 4
20

MENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

caccgcagtg acctggtgag tgggcgcctc ccggtgggcc ttagcatgaa ggagcagggg 4
 80
 gagttcctga gcctggccgt gctggacttg gcccagatgg ctogtgagca ggcccagcgc 5
 40
 ccaggagagc tgctgaagac ggtcagttac aaagcctgtc tgccgcccag cctgcgcgat 6
 00
 gtgatccagg gccagaactt cgtgacacgc aggcgcatcc gcaggaccgt ggtcttggcg 6
 60
 ctgcgcgtgt ggtcgcctgc caggccgacc gctacggctc atggccaagt atatctggac 7
 20
 ctggagcggc tacatccagc ggccaccacc gagaccttcc gtgtggggct cccgggcgcc 7
 80
 caggaggagc cggggcttct gcgtgtggcg ggggacaacg gcatctcctg gagctccggg 8
 40
 gaccaggagc ttttccagac cttctgtgac tttccggaaa tcgtggatgt cagcatcaag 9
 00
 cagcccacgt gtgggtccgg caggagcac cggctggcca ctgtcaccag gatggacggc 9
 60
 cacatcctgg aagcggagtt tccggggctg cctgaggcgc tgtctttcgt ggccctcgtg 10
 20
 gatgggtact tccgcctgat ctgcgactcc aggcattatt tctgcaagga ggtggcggcg 10
 80
 ccacggctgc tggaggagga ggcggagctg tgccatggac ccatcacgtt agactttgcc 11
 40
 atccacaagc tgaaggccgc tgcgtccctc ccaggcacct atattctccg ccgcagcccc 12
 00
 caggactatg acagctttct tcttaccgcc tgcgtccaga ctctcttgg ccccgactac 12
 60
 aagggtgcc tcatccgcca ggaccccagc ggggctttct ccctggttgg cctcagcagc 13
 20
 cccacagaag cctgcgggac gtgcttgagc tgctggaatt ctgggctgcg agtagacggt 13
 80

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gctgccctga acctaacatc ctgctgcgct cccagaccca aggaaaagtc caatttgatc 14
 40
 gtggtgcgaa ggggctgcac ccccgcgctt gcccctggct gctccccgtc ctgctgtgcg 15
 00
 ctgacacagc tgagcttcca cacaattcca acggacagcc tgggacacga gaacctgggt 15
 60
 cacggttctt ttaccaagat cttccgtggc cgcaggcggg aggtcgtgga tggtagagaca 16
 20
 catgactcgg aagtcctcct gaaggtcatg gactccagac atcggaactg catggagtct 16
 80
 tttctggaag ccgcaagctt gatgagccaa gtatcctacc cgcacctggg gttactgcac 17
 40
 ggcgtctgca tggctggaga cagcatcatg gtgcaggaat ttgtgtatct aggagcaatt 18
 00
 gacatgtacc tgcgcaagcg tggccacctg gtgtcagcca gctggaaact gcaggtgacc 18
 60
 aagcagctgg catatgccct taactacttg gaggacaaag gccttcctca cggcaacgtc 19
 20
 tcagcacgga aggtgctcct ggctcgtgag ggggggtgatg ggaatccacc tttcattaag 19
 80
 ctgagtgatc ctggtgtcag tcccactgtg ctgagcctgg aaatgctcac cgacagaata 20
 40
 ccctgggtgg cccccgaatg tctccaggag gctcagacac tctgcttgga ggctgacaag 21
 00
 tgggggcttg gagccaccac gtgggagggtg ttcagcgggg gacccgcca catcacctcg 21
 60
 ctggagcccg ccaaaaagct gaagttctat gaggaccagg gacagctgcc cgctctcaaa 22
 20
 tggacagaac tggcgggact tatcacacag tgcattggct atgattcctgg ccggcgcccc 22
 80
 tccttccgag ctatcctcag agacctcaac ggcctcatta catcagatta cgagctcctc 23
 40

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

tcagacccca cacctggcat cccgagtcct cgagatgagc tgtgcggtgg cgcccagctc 24
 00
 tatgcctgcc aggaccccg ccatattcgag gagagacacc ttaagtacat ctctttgctg 24
 60
 ggcaagggca actttggcag cgtggagctg tgccgctatg accccctgga caatacgga 25
 20
 cccctggtgg cagtgaaca gctacagcac agcgggccag accagcagag ggacttccag 25
 80
 cgggagattc agatccttaa ggctctgcac agcgacttca tcgtcaagta ccggggagtc 26
 40
 agctatgggc caggtcgcca gagcctgcgg ttggtgatgg agtacctgcc cagcggctgc 27
 00
 ctgcgagact tcctgcagcg ccatcgcgcg gccctgcaca ccgaccgcct actgctgttc 27
 60
 gcttggcaga tctgcaaggg catggagtac ctgggtgcgc gccgctgcgt acaccgtgac 28
 20
 ctggctgcgc gcaacatctt ggtggagagc gaggetcatg tgaagatcgc ggactttggc 28
 80
 ctcgctaagc tgctgcccct gggaaaggac tactacgtgg tccgcgagcc tggccaaagc 29
 40
 cccatctttt ggtatgcccc ggagtcccta tctgacaaca tcttctcccg ccaatctgac 30
 00
 gtgtggagct tcggagtggg gttgtacgag ctcttcacct actgcgacaa gagctgcagc 30
 60
 ccatccgctg agttcctgcg catgatgggg cctgagcgtg aaggaccccc gctctgccgc 31
 20
 ctccctggagc tgctggcaga gggccgacgc ctcccaccac ctcccacctg ccccaccgag 31
 80
 gttcaggagc tcatgcagct gtgcgtggcg ccagccgca cgaccggcca gccttcggca 32
 40
 ccctga 32
 46

TENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

```

<210> 24
<211> 1518
<212> DNA
<213> Mus musculus

<400> 24
atggcaaggc gaagctcccg ggtctcctgg ctggcctttg aaggctggga atctagggac
60
ctgcctcggg tgagccctag attgttcgga gcttggcacc ccgcgcctgc tgcagctagg 1
20
atgccaacgc gctgggcccc tgggactcaa tgcattgacca agtgtgagaa ctctcgcccc 1
80
aagcccgggt agctagcctt tcgaaagggg gacatgggtga ccatcttgga ggcctgtgag 2
40
gacaagagct ggtaccgagc caagcaccat ggcagtgggc aggaagggtc gctggcgggc 3
00
gctgctctgc gacagcggga ggccctctcc acagaccca agctcagcct catgccatgg 3
60
tttcatggca agatctccgg ccaggaagcc atacagcagc tgcagccacc cgaggacggg 4
20
ctgttccttg tgagggaatc agctcgtcac cctggagact atgtcttgtg tgtcagtttc 4
80
ggccgtgacg tcatccacta ccgtgttttg catcgagatg ggcacctcac catcgatgag 5
40
gccgtgtgtt tctgtaacct gatggacatg gtggagcact acaccaagga caagggggcc 6
00
atctgcacca agctggtgaa gccaaggagg aaacagggcg caaagtctgc agaggaggag 6
60
ctcgccaagg ctggctggct actcgacctg cagcatctga ctctgggagc acagattgga 7
20
gagggggagt ttggagccgt cctacagggg gagtacctgg gacagaaggt ggctgtgaag 7
80
aatatcaagt gtgatgtgac agcccaggcc ttcctggatg agacggctgt gatgacgaag 8

```

CENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND
40

```

ctgcagcaca ggaacctagt gcgactcctg ggtgtgatcc tgcaccacgg cttgtacatt    9
00

gtcatggagc acgtgagcaa gggcaacctg gtgaacttcc tgcgcacgcg gggccgtgct    9
60

cttgtgagca cctctcagct tctgcagttt gctcttcatg ttgctgaagg catggaatac   10
20

ctggagagca agaagctggt gcaccgggac ctggctgctc ggaacatcct ggtctctgag   10
80

gacttggtgg ccaaggtcag tgactttggc ttagccaagg cagagcgcaa ggggctggac   11
40

tcaagccggc tgccagtcaa gtggacggca cctgaggctc tcaaaaacgg gcggttctcc   12
00

agcaagtcgg atgtctggag ttttggggtg ctgttgtggg aagtcttctc ttatggaaga   12
60

gccccatacc ccaagatgtc gctaaaggag gtttcagagg ctgtggagaa gggttaccgc   13
20

atggagcccc ccgatggctg cccaggctct gtgcacaccc tcatgggtag ctgctgggag   13
80

gcagagcctg cgcgccgacc acccttccgc aaaatagtgg agaagctggg ccgtgagctc   14
40

cgcagtgtgg gtgtctcggc ccccgctggg ggacaggagg ctgagggctc agctcccaca   15
00

cggagccagg acccctga                                     15
18

```

<210> 25
 <211> 1490
 <212> DNA
 <213> Mus musculus

<400> 25
 tggagccctt cctcaggaag cggtcactt tcttgtcctt tttctgggat aagatatggc
 60

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

cagcggatga atcggaggaa gacatcccca ggatccaggg acacgacgac aaccagtgcc 1
 20
 cgagagcaagc cgctgccgtt gaaccttgta gcttcccagc cccacgcgcc cgactcttcc 1
 80
 gcgcgctcta cgacttcact gctcgatgtg cagaggaact gagcgtcagc ggtggggaca 2
 40
 gactctacgc cctcaaggag gagggggact acatctttgc ccaaaggctc tctgggtccac 3
 00
 ccagcaccgg actagttcct gtcacctacc ttgccaaggc taccgccggag ccgccctcag 3
 60
 accaaccttg gtacttcagt gggatcagca gggctcaggc ccagcagttg ctcttgcttc 4
 20
 ctgccaatgc accagggggc ttctcatcc ggcccagcga aagcagcatc gggggctatt 4
 80
 ctctatcagt cagggcccag gccaaagtct gccactaccg catctgcatg gcaccagtg 5
 40
 gcagcctcta tctgcaggag ggccaactct tcccagcct ggatgcactg ctggcttact 6
 00
 acaagaccaa ctggaagctg atccagaacc ctctgctgca gccctgcata cccagatac 6
 60
 ccttggttca ggacgagtgg gaacgaccac gttcagaatt tgtcttcgga agaaagctgg 7
 20
 gtgaaggttt cttcggggag gtgtgggaag gcctgtggct gggctctatc cctgtggcag 7
 80
 tgaaggttat caaatcagct gacatgaagc tggcagacct caccaaggag attgaggcac 8
 40
 tgaagagctt gaggcagtag aggctgatcc ggctgcacgc tatatgttcc ctcggtgaac 9
 00
 ctgtgtacat cgttactgaa ctcatgggca agggcaactt gcaagtctac ctgggcagct 9
 60
 ctgagggaaa ggccctgagc ctgccccatc tactgggatt tgccctgccag gtagctgagg 10
 20

FENT OR GRAFT COATED OR IMPREGNATED WITH PROTEIN TYROSINE KINASE INHIBITORS AND

gcatgagcta cctggaggag cggcgtgtcg tccaccggga ctgggctgcc aggaacgtgc 10
80

tggtgggtga tgacctcacc tgcaaggtag ctgattttgg cctggccaga ctgctcaagg 11
40

atgatgtcta ctcccccaagc agtgggtcca agatccctgt caagtggacg gcacctgagg 12
00

ctgctaatta ccgtgtcttt tccc aaaagt cagatgtctg gtcctttggc atcctgctgt 12
60

atgaggtctt cacttatggc cagtgtccct atgaaggaat gaccaaccat gagacgctac 13
20

agcagattag tcgtggatac cggctgccac gccagctgt ctgccagca gaggtctatg 13
80

tgctcatggt agagtgtgg aagggcagcc ctgaggagcg tcccaccttt gccatactga 14
40

gggagaagct gaatgccata aacagacgcc tccatctggg cctcacgtga 14
90